Hologic (HOLX) 10-Q 29 Jan 20 2020 Q1 Quarterly report Financial data

Cover Page

Cover Page - shares	3 Months Ended
	Dec. 28, 2019	Jan. 23, 2020
Cover page.
Title of 12(b) Security	Common Stock, $0.01 par value
Document Transition Report	false
Document Quarterly Report	true
Entity Incorporation, State or Country Code	DE
Entity Address, Postal Zip Code	01752
Entity File Number	1-36214
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Dec. 28, 2019
Document Fiscal Year Focus	2020
Document Fiscal Period Focus	Q1
Entity Registrant Name	HOLOGIC, INC
Entity Central Index Key	0000859737
Current Fiscal Year End Date	--09-28
Entity Filer Category	Large Accelerated Filer
Entity Emerging Growth Company	false
Entity Small Business	false
Entity Common Stock, Shares Outstanding		263,302,012
Entity Shell Company	false
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
City Area Code	(508)
Local Phone Number	263-2900
Entity Tax Identification Number	04-2902449
Entity Address, Address Line One	250 Campus Drive,
Entity Address, City or Town	Marlborough,
Entity Address, State or Province	MA
Trading Symbol	HOLX
Security Exchange Name	NASDAQ

Consolidated Statements of Inco

Consolidated Statements of Income - USD ($) shares in Thousands, $ in Millions	3 Months Ended
	Dec. 28, 2019	Dec. 29, 2018
Revenues:
Product	$ 699.3	$ 683.1
Service and other	151.2	147.6
Revenues	850.5	830.7
Costs of revenues:
Product	237.5	232.1
Amortization of acquired intangible assets	63.6	81
Impairment of intangible assets	25.8	0
Service and other	89.8	83.5
Gross profit	433.8	434.1
Operating expenses:
Research and development	61.2	53.2
Selling and marketing	144.9	146
General and administrative	88.5	78.6
Amortization of acquired intangible assets	9.1	14.1
Impairment of intangible assets	4.4	0
Restructuring charges	0.9	1.7
Operating expenses	309	293.6
Income from operations	124.8	140.5
Interest income	2.1	1.3
Interest expense	(32.8)	(36.1)
Debt extinguishment loss	0	(0.8)
Other income (expense), net	3.3	(0.6)
Income before income taxes	97.4	104.3
(Benefit) provision for income taxes	(288.4)	5.7
Net income	386.1	98.6
Noncontrolling Interest in Net Income (Loss) Other Noncontrolling Interests, Redeemable	(0.3)	0
Net income	$ 385.8	$ 98.6
Net income per common share attributable to Hologic:
Basic (in usd per share)	$ 1.44	$ 0.36
Diluted (in usd per share)	$ 1.43	$ 0.36
Weighted average number of shares outstanding:
Basic (in shares)	267,893	270,590
Diluted (in shares)	269,721	272,372

Consolidated Statements of Comp

Consolidated Statements of Comprehensive Loss - USD ($) $ in Millions	3 Months Ended
	Dec. 28, 2019	Dec. 29, 2018
Statement of Comprehensive Income [Abstract]
Net income	$ 385.8	$ 98.6
Changes in foreign currency translation adjustment	8.3	(3.2)
Changes in value of hedged interest rate swaps and interest rate caps, net of tax of $1.7 and $0.5 for the three months ended December 28, 2019 and December 29, 2018.	4	(3.9)
Loss reclassified from accumulated other comprehensive loss to the statements of income	1.3	0.7
Other comprehensive income (loss)	13.6	(6.4)
Comprehensive income	399.4	92.2
Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Noncontrolling Interest	0.3
Noncontrolling Interest in Net Income (Loss) Other Noncontrolling Interests, Redeemable	(0.3)	0
Comprehensive Income	$ 399.7	$ 92.2

Consolidated Statements of Co_2

Consolidated Statements of Comprehensive Loss (Parenthetical) - USD ($) $ in Millions	3 Months Ended
	Dec. 28, 2019	Dec. 29, 2018
Statement of Comprehensive Income [Abstract]
Changes in unrealized holding gains and losses on available-for-sale securities. tax		$ 0
Changes in pension plans, tax		0
Changes in value of hedged interest rate caps, tax	$ 1.7	$ 0.5

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($) $ in Millions	Dec. 28, 2019	Sep. 28, 2019
Statement of Financial Position [Abstract]
Cash less assets held for sale	$ 370.8	$ 601.8
Current assets:
Accounts receivable, less reserves of $11.7 and $17.8, respectively	581.8	648.7
Inventories	380.8	444.9
Prepaid income taxes	30.9	34.9
Prepaid expenses and other current assets	62.7	62.8
Assets Held-for-sale, Not Part of Disposal Group, Current	210.6	0
Total current assets	1,637.6	1,793.1
Property, plant and equipment, net	452	470.9
Intangible assets, net	1,367	1,459.8
Goodwill	2,594.2	2,563.7
Other assets	261.1	154.6
Total assets	6,311.9	6,442.1
Current liabilities:
Current portion of long-term debt	302.2	271.4
Accounts payable	123.7	186.5
Accrued expenses	381.5	430.9
Deferred revenue	156.2	179.5
Current portion of capital lease obligations	1.8	1.8
Assets Held-for-sale, Not Part of Disposal Group, Current, Other	77.9	0
Total liabilities and stockholders’ equity	6,311.9	6,442.1
Total current liabilities	1,043.3	1,070.1
Long-term debt, net of current portion	2,769.4	2,783.6
Finance lease obligations - long term (capital lease obligations in 2019)	18.8	19.2
Deferred income tax liabilities	5.7	275.3
Deferred revenue	15.3	15.8
Other long-term liabilities	201.7	162.4
Stockholders’ equity:
Preferred stock, $0.01 par value – 1,623 shares authorized; 0 shares issued	0	0
Common stock, $0.01 par value – 750,000 shares authorized; 293,339 and 292,323 shares issued, respectively	2.9	2.9
Additional paid-in-capital	5,749.8	5,769.8
Accumulated deficit	(2,302.3)	(2,688.7)
Treasury stock, at cost – 29,462 and 24,638 shares, respectively	(1,170.9)	(926)
Accumulated other comprehensive loss	(28.7)	(42.3)
Total Hologic's stockholders’ equity	2,250.8	2,115.7
Stockholders' Equity Attributable to Noncontrolling Interest	6.9	0
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest	$ 2,257.7	$ 2,115.7

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parenthetical) - USD ($) $ in Millions	Dec. 28, 2019	Sep. 28, 2019
Statement of Financial Position [Abstract]
Accounts receivable, reserves	$ 11.7	$ 17.8
Preferred stock, par value (in dollars per share)	$ 0.01	$ 0.01
Preferred stock, authorized (in shares)	1,623,000	1,623,000
Preferred stock, issued (in shares)	0	0
Common stock, par value (in dollars per share)	$ 0.01	$ 0.01
Common stock, authorized (in shares)	750,000,000	750,000,000
Common stock, issued (in shares)	293,339,000	292,323,000
Treasury stock (in shares)	29,462,000	24,638,000

Consolidated Statements of Stoc

Consolidated Statements of Stockholders' Equity - USD ($) shares in Thousands, $ in Thousands	Total	Common Stock	Additional Paid-in Capital	Retained Earnings	Total	Treasury Stock	Share Repurchase ProgramTreasury Stock
Redeemable Noncontrolling Interest, Equity, Other, Carrying Amount	$ 0
Balance (in shares) at Sep. 29, 2018		289,900				19,812
Balance at Sep. 29, 2018	2,428,800	$ 2,900	$ 5,671,300	$ (2,494,000)	$ (25,500)	$ (725,900)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Exercise of stock options (in shares)		373
Exercise of stock options	9,100		9,100
Vesting of restricted stock units, net of shares withheld for employee taxes ( in shares)		575
Vesting of restricted stock units, net of shares withheld for employee taxes	(11,600)		(11,600)
Stock-based compensation expense	17,100		17,100
Net income	98,600
Other comprehensive income activity	(6,400)				(6,400)
Repurchase of common stock (in shares)						3,712
Repurchase of common stock	150,100					$ 150,100
Balance (in shares) at Dec. 29, 2018		290,848				23,524
Balance at Dec. 29, 2018	2,394,400	$ 2,900	5,685,900	(2,386,500)	(31,900)	$ (876,000)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Noncontrolling Interest in Net Income (Loss) Other Noncontrolling Interests, Redeemable	0
Net income	98,600
Accelerated share repurchase agreement	0
Payments to Noncontrolling Interests	0
Redeemable Noncontrolling Interest, Equity, Other, Carrying Amount	0
Accounting standard transition adjustment | Accounting Standards Update 2014-09	6,400			6,400
Accounting standard transition adjustment | Accounting Standards Update 2016-16	(2,500)			(2,500)
Exercise of stock options (in shares)		454
Exercise of stock options	11,600		11,600
Vesting of restricted stock units, net of shares withheld for employee taxes ( in shares)		33
Vesting of restricted stock units, net of shares withheld for employee taxes	(400)		(400)
Common stock issued under the employee stock purchase plan (in shares)		226
Common stock issued under the employee stock purchase plan	7,900		7,900
Stock-based compensation expense	17,500		17,500
Net income	(272,600)
Other comprehensive income activity	1,400				1,400
Balance (in shares) at Mar. 30, 2019		291,561				23,524
Balance at Mar. 30, 2019	2,159,800	$ 2,900	5,722,500	(2,659,100)	(30,500)	$ (876,000)
Redeemable Noncontrolling Interest, Equity, Other, Carrying Amount	0
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Exercise of stock options (in shares)		108
Exercise of stock options	3,100		3,100
Vesting of restricted stock units, net of shares withheld for employee taxes ( in shares)		21
Vesting of restricted stock units, net of shares withheld for employee taxes	(500)		(500)
Stock-based compensation expense	13,900		13,900
Net income	93,900
Other comprehensive income activity	(3,700)				(3,700)
Repurchase of common stock (in shares)						1,114
Repurchase of common stock	50,000					$ 50,000
Balance (in shares) at Jun. 29, 2019		291,690				24,638
Balance at Jun. 29, 2019	2,216,500	$ 2,900	5,739,000	(2,565,200)	(34,200)	$ (926,000)
Redeemable Noncontrolling Interest, Equity, Other, Carrying Amount	0
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Exercise of stock options (in shares)		369
Exercise of stock options			9,000
Vesting of restricted stock units, net of shares withheld for employee taxes ( in shares)		16
Vesting of restricted stock units, net of shares withheld for employee taxes			(300)
Common stock issued under the employee stock purchase plan (in shares)		248
Common stock issued under the employee stock purchase plan			8,600
Stock-based compensation expense			13,500
Net income	(123,500)
Other comprehensive income activity					(8,100)
Balance (in shares) at Sep. 28, 2019		292,323				24,638
Balance at Sep. 28, 2019	2,115,700	$ 2,900	5,769,800	(2,688,700)	(42,300)	$ (926,000)
Redeemable Noncontrolling Interest, Equity, Other, Carrying Amount	0
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest	2,115,700
Noncontrolling Interest, Increase from Business Combination	8,600
Exercise of stock options (in shares)		540
Exercise of stock options			13,800
Vesting of restricted stock units, net of shares withheld for employee taxes ( in shares)		476
Vesting of restricted stock units, net of shares withheld for employee taxes			(10,900)
Stock-based compensation expense			18,100
Net income	385,800
Other comprehensive income activity					13,600
Repurchase of common stock (in shares)						1,545	3,279
Repurchase of common stock	80,900					$ 80,900	$ (164,000)
ASR portion flowing through APIC						$ (41,000)
Balance (in shares) at Dec. 28, 2019		293,339				29,462
Balance at Dec. 28, 2019	2,250,800	$ 2,900	$ 5,749,800	(2,302,300)	$ (28,700)	$ (1,170,900)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Noncontrolling Interest in Net Income (Loss) Other Noncontrolling Interests, Redeemable	(300)
Net income	386,100
Accelerated share repurchase agreement	(205,000)
Payments to Noncontrolling Interests	(1,400)
Redeemable Noncontrolling Interest, Equity, Other, Carrying Amount	6,900
Accounting standard transition adjustment | Accounting Standards Update 2018-01 [Member]				$ 300
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest	$ 2,257,700

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($) $ in Millions	3 Months Ended
	Dec. 28, 2019	Mar. 30, 2019	Dec. 29, 2018
OPERATING ACTIVITIES
Net income	$ 385.8	$ (272.6)	$ 98.6
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation	21.6		23.7
Amortization of acquired intangibles	72.8		95.1
Stock-based compensation expense	18.1		17.1
Deferred income taxes	(327.9)		(50)
Intangible asset impairment charges	30.2		0
Other adjustments and non-cash items	0.5		11.7
Changes in operating assets and liabilities, excluding the effect of acquisitions:
Accounts receivable	17.6		0.4
Inventories	(14.9)		(27.9)
Prepaid income taxes	1		2
Prepaid expenses and other assets	(2.6)		(1.8)
Accounts payable	(55.4)		(16)
Accrued expenses and other liabilities	(22.6)		(51.6)
Deferred revenue	(10.3)		3.3
Net cash provided by operating activities	113.9		104.6
INVESTING ACTIVITIES
Acquisition of businesses, net of cash acquired	(11.8)		(106.6)
Capital expenditures	(11.4)		(9.5)
Increase in equipment under customer usage agreements	(20.1)		(13.1)
Purchase of insurance contracts	2.4		0
Other activity	0		(1.5)
Net cash used in investing activities	(45.7)		(130.7)
FINANCING ACTIVITIES
Proceeds from long-term debt	0		1,500
Repayment of long-term debt	(9.4)		(1,462.5)
Proceeds from amounts borrowed under revolving credit line	0		480
Repayments of amounts borrowed under revolving credit line	0		(695)
Proceeds from amounts borrowed under accounts receivable securitization agreement	16		0
Payments to Noncontrolling Interests	(1.4)		0
Payment of debt issuance costs	0		(2.7)
Payment of acquired long-term debt	0		(2.5)
Payment of deferred acquisition consideration	(16.6)		0
Accelerated share repurchase agreement	(205)		0
Repurchase of common stock	(80.9)		(147)
Proceeds from issuance of common stock pursuant to employee stock plans	18.7		13.5
Payment of minimum tax withholdings on net share settlements of equity awards	(10.9)		(11.6)
Payments under finance lease obligations	(0.4)		(0.4)
Net cash used in financing activities	(289.9)		(328.2)
Effect of exchange rate changes on cash and cash equivalents	1.4		(1.3)
Net decrease in cash and cash equivalents	(220.3)		(355.6)
Cash and cash equivalents, beginning of period		$ 311.1	666.7
Cash and cash equivalents, end of period	$ 381.5		$ 311.1

Basis of Presentation

Basis of Presentation	3 Months Ended
	Dec. 28, 2019
Basis of Presentation [Abstract]
Basis of Presentation	Basis of Presentation The consolidated financial statements of Hologic, Inc. (“Hologic” or the “Company”) presented herein have been prepared pursuant to the rules of the Securities and Exchange Commission (“SEC”) for quarterly reports on Form 10-Q and do not include all of the information and disclosures required by U.S. generally accepted accounting principles (“GAAP”) for annual financial statements. These financial statements should be read in conjunction with the consolidated financial statements and related notes for the fiscal year ended September 28, 2019 included in the Company’s Form 10-K filed with the SEC on November 27, 2019. In the opinion of management, the financial statements and notes contain all adjustments (consisting of normal recurring accruals and all other necessary adjustments) considered necessary for a fair presentation of the Company’s financial position, results of operations and cash flows for the periods presented. The consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries. All intercompany transactions and balances have been eliminated in consolidation. The preparation of financial statements in conformity with GAAP requires management to make significant estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting periods. Actual results could differ from management’s estimates if past experience or other assumptions do not turn out to be substantially accurate. Operating results for the three months ended December 28, 2019 are not necessarily indicative of the results to be expected for any other interim period or the entire fiscal year ending September 26, 2020 . Recently Adopted Accounting Pronouncements In February 2016, the Financial Accounting Standards Board (the"FASB") issued Accounting Standards Update ("ASU") No. 2016-02, Leases (Topic 842), referred to as ASC 842. The purpose of ASU 2016-02 is to increase the transparency and comparability among organizations by recognizing lease assets and liabilities on the balance sheet, including those previously classified as operating leases under U.S. GAAP, and disclosing key information about leasing arrangements. ASC 842, as amended, is effective for public entities for annual periods beginning after December 15, 2018, including interim periods within those annual periods and was effective for the Company in fiscal 2020. The Company adopted the standard using the transition method provided by ASC Update No. 2018-11, Leases (Topic 842): Targeted Improvements. Under this method, the Company applied the new leasing rules on September 29, 2019, rather than at the earliest comparative period presented in the financial statements. Prior periods were presented in accordance with the existing lease guidance under ASC 840. Upon transition, the Company applied the package of practical expedients permitted under ASC 842 transition guidance to its entire lease portfolio at September 29, 2019. As a result, the Company was not required to reassess (i) whether any expired or existing contracts are or contain leases, (ii) the classification of any expired or existing leases, and (iii) initial direct costs for any existing leases. Furthermore, as a lessee the Company elected to combine lease and non-lease components together for the majority of its leases. As a result, for these applicable classes of underlying assets, the Company accounted for each separate lease component and the non-lease components associated with that lease component as a single lease component. Under ASC 842 as a lessor, in instances where the Company places instruments (or equipment) at customer sites as part of its reagent rental contracts, certain of the Company's reagent rental contracts could be classified as sales-type leases. Under sales-type leases there is accelerated expense recognition for the cost of the placed equipment and potentially up-front revenue in the event there are fixed rental payments, a portion of which would be allocated to the equipment. The Company does not expect to have a significant amount of sales-type leases. Under ASC 840, all instruments placed under the Company's reagent rental programs were classified as operating leases and instrument revenue and cost were recognized over the term of the contract. Upon adoption of the new lease standard, the Company recognized operating lease right-of-use assets and finance lease right-of-use assets of $91.7 million and $10.2 million , respectively, and corresponding operating lease liabilities and finance lease liabilities of $96.6 million and $21.0 million , respectively. This includes the recording of the Company’s existing capital lease as a finance lease at transition. In addition, the Company derecognized $32.6 million of property, plant and equipment and $35.2 million of finance lease obligations recorded in accrued expenses and other long-term liabilities associated with two previously existing build-to-suit lease arrangements. Right-of-use assets and corresponding liabilities for these build-to-suit lease arrangements are included within the total amount recognized upon adoption of the new lease standard. The Company’s adoption of ASC 842 is more fully described in Note 3. In August 2017, the FASB issued ASU No. 2017-12, Derivatives and Hedging (Topic 815): Targeted Improvements to Accounting for Hedging Activities . The guidance requires certain changes to the presentation of hedge accounting in the financial statements and also simplifies the application of hedge accounting and expands the strategies that qualify for hedge accounting. The Company adopted the standard in the first quarter of fiscal 2020. The adoption of ASU 2017-12 did not have a material effect on the Company's consolidated financial statements. Subsequent Events Consideration The Company considers events or transactions that occur after the balance sheet date but prior to the issuance of the financial statements to provide additional evidence for certain estimates or to identify matters that may require additional disclosure. Subsequent events have been evaluated as required. Other than the sale of the Medical Aesthetics business, which was completed on December 30, 2019 (the second quarter of fiscal 2020), there were no material recognized or unrecognized subsequent events affecting the unaudited consolidated financial statements as of and for the three months ended December 28, 2019 . See Note 6 for additional information.

Revenue

Revenue	3 Months Ended
	Dec. 28, 2019
Revenue from Contract with Customer [Abstract]
Revenue	Revenue The Company accounts for revenue pursuant to ASC Update No. 2014-09, Revenue from Contracts with Customer (ASC 606) and generates revenue from the sale of its products, primarily medical imaging systems and related components and software, medical aesthetic treatment systems, diagnostic tests/assays and surgical disposable products, and related services, which are primarily support and maintenance services on its medical imaging systems and aesthetic treatment systems (divested in the second quarter of fiscal 2020), and to a lesser extent installation, training and repairs. The Company's products are sold primarily through a direct sales force, and within international markets, there is more reliance on distributors and resellers. Revenue is recorded net of sales tax. The following table provides revenue from contracts with customers by business and geographic region on a disaggregated basis: Three Months Ended December 28, 2019 Business ( in millions ) United States International Total Diagnostics: Cytology & Perinatal $ 77.5 $ 43.5 $ 121.0 Molecular Diagnostics 142.1 36.4 178.5 Blood Screening 12.0 — 12.0 Total $ 231.6 $ 79.9 $ 311.5 Breast Health: Breast Imaging $ 209.4 $ 65.4 $ 274.8 Interventional Breast Solutions 47.1 9.2 56.3 Total $ 256.5 $ 74.6 $ 331.1 GYN Surgical $ 98.8 $ 20.3 $ 119.1 Medical Aesthetics $ 30.9 $ 34.4 $ 65.3 Skeletal Health $ 14.9 $ 8.6 $ 23.5 $ 632.7 $ 217.8 $ 850.5 Three Months Ended December 29, 2018 Business (in millions) United States International Total Diagnostics: Cytology & Perinatal $ 79.2 $ 38.9 $ 118.1 Molecular Diagnostics 134.1 30.2 164.3 Blood Screening 14.2 — 14.2 Total $ 227.5 $ 69.1 $ 296.6 Breast Health: Breast Imaging $ 206.5 $ 63.2 $ 269.7 Interventional Breast Solutions 46.1 8.9 55.0 Total $ 252.6 $ 72.1 $ 324.7 GYN Surgical $ 91.1 $ 17.3 $ 108.4 Medical Aesthetics $ 37.3 $ 42.5 $ 79.8 Skeletal Health $ 13.3 $ 7.9 $ 21.2 $ 621.8 $ 208.9 $ 830.7 Three Months Ended Geographic Regions ( in millions ) December 28, 2019 December 29, 2018 United States $ 632.7 $ 621.8 Europe 109.4 101.1 Asia-Pacific 70.2 69.6 Rest of World 38.2 38.2 $ 850.5 $ 830.7 The following table provides revenue recognized by source: Three Months Ended Revenue by type (in millions) December 28, 2019 December 29, 2018 Capital equipment, components and software $ 232.9 $ 248.3 Consumables 466.4 434.8 Service 145.0 141.8 Other 6.2 5.8 $ 850.5 $ 830.7 The Company considers revenue to be earned when all of the following criteria are met: the Company has a contract with a customer that creates enforceable rights and obligations; promised products or services are identified; the transaction price, or the amount the Company expects to receive, including an estimate of uncertain amounts subject to a constraint to ensure revenue is not recognized in an amount that would result in a significant reversal upon resolution of the uncertainty, is determinable; and the Company has transferred control of the promised items to the customer. A performance obligation is a promise in a contract to transfer a distinct good or service to the customer, and is the unit of account in the contract. The transaction price for the contract is measured as the amount of consideration the Company expects to receive in exchange for the goods and services expected to be transferred. A contract's transaction price is allocated to each distinct performance obligation and recognized as revenue when, or as, control of the distinct good or service is transferred. Transfer of control for the Company's products is generally at shipment or delivery, depending on contractual terms, but occurs when title and risk of loss transfers to the customer which represents the point in time when the customer obtains the use of and substantially all of the remaining benefit of the product. As such, the Company's performance obligation related to product sales is satisfied at a point in time. Revenue from support and maintenance contracts, extended warranty and professional services for installation, training and repairs is recognized over time based on the period contracted or as the services are performed as these methods represent a faithful depiction of the transfer of goods and services. The Company recognizes a receivable when it has an unconditional right to payment. Payment terms are typically 30 days in the U.S. but may be longer in international markets. The Company treats shipping and handling costs performed after a customer obtains control of the good as a fulfillment cost and records these costs within costs of product revenue when the corresponding revenue is recognized. The Company also places instruments (or equipment) at customer sites but retains title to the instrument. The customer has the right to use the instrument for a period of time, and the Company recovers the cost of providing the instrument through the sales of disposables, namely tests and assays in Diagnostics and handpieces in GYN Surgical. These types of agreements include an embedded lease, which is generally an operating lease, for the right to use an instrument and no instrument revenue is recognized at the time of instrument delivery. The Company recognizes a portion of the revenue allocated to the embedded lease concurrent with the sale of disposables over the term of the agreement. Some of the Company's contracts have multiple performance obligations. For contracts with multiple performance obligations, the Company allocates the transaction price to each performance obligation using its best estimate of the standalone selling price of each distinct good or service in the contract. The Company determines its best estimate of stand-alone selling price using average selling prices over 3 to 12 month periods of data depending on the products or nature of the services coupled with current market considerations. If the product or service does not have a history of sales or if sales volume is not sufficient, the Company relies on prices set by its pricing committees or applicable marketing department adjusted for expected discounts. Variable Consideration The Company exercises judgment in estimating variable consideration, which includes volume discounts, sales rebates, product returns and other adjustments. These amounts are recorded as a reduction to revenue and classified as a current liability. The Company bases its estimates for volume discounts and sales rebates on historical information to the extent it is reasonable to be used as a predictive tool of expected future rebates. To the extent the transaction price includes variable consideration, the Company applies judgment in constraining the estimated variable consideration due to factors that may cause reversal of revenue recognized. The Company evaluates constraints based on its historical and projected experience with similar customer contracts. The Company's contracts typically do not provide the right to return product. In general, estimates of variable consideration and constraints are not material to the Company's financial statements. Remaining Performance Obligations As of December 28, 2019, the estimated revenue expected to be recognized in the future related to performance obligations that are unsatisfied was approximately $500.7 million , excluding the Medical Aesthetics reportable segment due to the sale completed on December 30, 2019. This remaining performance obligation primarily relates to extended warranty and support and maintenance obligations in the Company's Breast Health and Skeletal Health reportable segments. The Company expects to recognize approximately 30% of this amount as revenue in 2020, 29% in 2021, 23% in 2022, 12% in 2023, and 6% thereafter. The Company has applied the practical expedient to not include remaining performance obligations related to contracts with original expected durations of one year or less in the amounts above. Contract Assets and Liabilities The Company discloses accounts receivable separately in the Consolidated Balance Sheets at their net realizable value. Contract assets primarily relate to the Company's conditional right to consideration for work completed but not billed at the reporting date. Contract assets at the beginning and end of the period, as well as the changes in the balance, were immaterial. Contract liabilities primarily relate to payments received from customers in advance of performance under the contract. The Company records a contract liability, or deferred revenue, when it has an obligation to provide service, and to a much lesser extent product, to the customer and payment is received or due in advance of performance. Deferred revenue primarily relates to support and maintenance contracts and extended warranty obligations within the Company's Breast Health and Skeletal Health reportable segments and the recently divested Medical Aesthetics segment. Contract liabilities are classified as other current liabilities and other long-term liabilities on the Consolidated Balance Sheets. The Company recognized revenue of $51.3 million in the three months ended December 28, 2019 that was included in the contract liability balance at September 28, 2019. Practical Expedients With the adoption of ASC 606, the Company elected to apply certain permitted practical expedients. In evaluating the cumulative-effect adjustment to retained earnings, the Company adopted the standard only for contracts that were not complete as of the date of adoption. For contracts that were modified prior to the adoption date, the Company elected to present the aggregate effect of all contract modifications in determining the transaction price and for the allocation to the satisfied and unsatisfied performance obligations. The Company applies a practical expedient to expense costs as incurred for costs to obtain a contract with a customer when the amortization period would have been one year or less. These costs solely comprise sales commissions and typically the commissions are incurred at the time of shipment of product and upon billings for support and maintenance contracts.

Leases (Notes)

Leases (Notes)	3 Months Ended
	Dec. 28, 2019
Leases [Abstract]
Leases	Leases Lessee Activity - Leases where Hologic is the Lessee The majority of the Company's facilities are occupied under operating lease arrangements with various expiration dates through 2035, some of which include options to extend the life of the lease, and some of which include options to terminate the lease within one year . The Company has operating leases for office space, land, warehouse and manufacturing space, vehicles and certain equipment. Leases with an initial term of 12 months or less are generally not recorded on the balance sheet and expense for these leases is recognized on a straight-line basis over the lease term. For leases executed in fiscal 2020 and later, the Company accounts for the lease components and the non-lease components as a single lease component. The Company's leases have remaining lease terms of one year to approximately 15 years , some of which may include options to extend the leases for up to 20 years and some include options to terminate early. These options have been included in the determination of the lease liability when it is reasonably certain that the option will be exercised. The Company does not have any leases that include residual value guarantees. The Company determines whether an arrangement is or contains a lease based on the unique facts and circumstances present at the inception of an arrangement. The right-of-use assets and related liabilities for operating leases are included in other assets, accrued expenses, and other long-term liabilities in the consolidated balance sheet as of December 28, 2019. As a result of the Cynosure acquisition, the Company has a finance lease for the facility that was previously Cynosure's U.S. headquarters. This lease was recorded as a capital lease under ASC 840 as of September 28, 2019. The right-of-use asset for the finance lease is included in property, plant and equipment, and the short-term and long-term liability are presented separately in the consolidated balance sheet as of December 28, 2019. Right-of-use assets represent the Company's right to use an underlying asset for the lease term and lease liabilities represent the Company's obligation to make lease payments arising from the lease contract. Operating lease liabilities and their corresponding right-of-use assets are recorded based on the present value of fixed lease payments over the expected lease term. The interest rate implicit in lease contracts is typically not readily determinable. As such, the Company utilizes the appropriate incremental borrowing rate, which is the rate incurred to borrow on a collateralized basis over a similar term at an amount equal to the lease payments in a similar economic environment. The weighted average discount rate utilized on the Company's operating and finance lease liabilities as of December 28, 2019 was 2.57% . The following table presents supplemental balance sheet information related to the Company's operating and finance leases: December 28, 2019 Balance Sheet Location Operating Leases Finance Lease Assets Lease right-of-use assets Other assets $ 89.6 $ — Lease right-of-use assets Property, plant and equipment $ — 9.9 Liabilities Operating lease liabilities (current) Accrued expenses $ 22.2 $ — Finance lease liabilities (current) Finance lease obligations - short term $ — $ 1.8 Operating lease liabilities (non-current) Other long-term liabilities $ 72.3 $ — Finance lease liabilities (non-current) Finance lease obligations - long term $ — $ 18.8 The finance lease was previously recorded as a capital lease in the consolidated balance at September 28, 2019, and the short-term and long-term liabilities were $1.8 million and $19.2 million , respectively. The following table presents the weighted average remaining lease term and discount rate information related to the Company's operating and finance leases: December 28, 2019 Operating Leases Finance Lease Weighted average remaining lease term 6.09 8.39 Weighted average discount rate 1.93 % 5.1 % The following table provides information related to the Company’s operating and finance leases: Three Months Ended December 28, 2019 Operating lease cost (a) $ 7.0 Finance lease cost - amortization of right-of-use assets $ 0.3 Finance lease cost - interest cost $ 0.3 Cash paid for amounts included in the measurement of lease liabilities: Operating cash flows from finance leases $ 0.3 Operating cash flows from operating leases 5.9 Financing cash flows from finance leases $ 0.4 Total cash paid for amounts included in the measurement of lease liabilities $ 6.6 ROU assets arising from entering into new operating lease obligations $ 1.4 (a) Includes short-term lease expense and variable lease costs, which were immaterial in the three months ended December 28, 2019. During the three months ended December 28, 2019, the non-cash impact of remeasuring the Company's right-of-use assets and operating lease liabilities was $2.4 million . The following table presents the future minimum lease payments under non-cancellable operating lease liabilities and finance lease as of December 28, 2019 : Fiscal Year Operating Leases Finance Lease 2020 remaining $ 17.8 $ 2.1 2021 22.2 2.8 2022 17.3 3.0 2023 10.7 3.0 2024 8.7 3.0 Thereafter 24.0 11.5 Total future minimum lease payments 100.7 25.4 Less: imputed interest (6.2 ) (4.8 ) Present value of lease liabilities $ 94.5 $ 20.6 Lessor Activity - Leases where Hologic is the Lessor Certain assets, primarily diagnostics instruments, are leased to customers under contractual arrangements that typically include an operating or sales-type lease as well as performance obligations for reagents and other consumables. These contractual arrangements are subject to termination provisions which are evaluated in determining the lease term for lease accounting purposes. Sales-type leases are not significant. Contract terms vary by customer and may include options to terminate the contract or options to extend the contract. Where instruments are provided under operating lease arrangements, some portion or the entire lease revenue may be variable and subject to subsequent non-lease component (e.g., reagent) sales. The allocation of revenue between the lease and non-lease components is based on stand-alone selling prices. Lease revenue represented approximately 3%
Leases	Leases Lessee Activity - Leases where Hologic is the Lessee The majority of the Company's facilities are occupied under operating lease arrangements with various expiration dates through 2035, some of which include options to extend the life of the lease, and some of which include options to terminate the lease within one year . The Company has operating leases for office space, land, warehouse and manufacturing space, vehicles and certain equipment. Leases with an initial term of 12 months or less are generally not recorded on the balance sheet and expense for these leases is recognized on a straight-line basis over the lease term. For leases executed in fiscal 2020 and later, the Company accounts for the lease components and the non-lease components as a single lease component. The Company's leases have remaining lease terms of one year to approximately 15 years , some of which may include options to extend the leases for up to 20 years and some include options to terminate early. These options have been included in the determination of the lease liability when it is reasonably certain that the option will be exercised. The Company does not have any leases that include residual value guarantees. The Company determines whether an arrangement is or contains a lease based on the unique facts and circumstances present at the inception of an arrangement. The right-of-use assets and related liabilities for operating leases are included in other assets, accrued expenses, and other long-term liabilities in the consolidated balance sheet as of December 28, 2019. As a result of the Cynosure acquisition, the Company has a finance lease for the facility that was previously Cynosure's U.S. headquarters. This lease was recorded as a capital lease under ASC 840 as of September 28, 2019. The right-of-use asset for the finance lease is included in property, plant and equipment, and the short-term and long-term liability are presented separately in the consolidated balance sheet as of December 28, 2019. Right-of-use assets represent the Company's right to use an underlying asset for the lease term and lease liabilities represent the Company's obligation to make lease payments arising from the lease contract. Operating lease liabilities and their corresponding right-of-use assets are recorded based on the present value of fixed lease payments over the expected lease term. The interest rate implicit in lease contracts is typically not readily determinable. As such, the Company utilizes the appropriate incremental borrowing rate, which is the rate incurred to borrow on a collateralized basis over a similar term at an amount equal to the lease payments in a similar economic environment. The weighted average discount rate utilized on the Company's operating and finance lease liabilities as of December 28, 2019 was 2.57% . The following table presents supplemental balance sheet information related to the Company's operating and finance leases: December 28, 2019 Balance Sheet Location Operating Leases Finance Lease Assets Lease right-of-use assets Other assets $ 89.6 $ — Lease right-of-use assets Property, plant and equipment $ — 9.9 Liabilities Operating lease liabilities (current) Accrued expenses $ 22.2 $ — Finance lease liabilities (current) Finance lease obligations - short term $ — $ 1.8 Operating lease liabilities (non-current) Other long-term liabilities $ 72.3 $ — Finance lease liabilities (non-current) Finance lease obligations - long term $ — $ 18.8 The finance lease was previously recorded as a capital lease in the consolidated balance at September 28, 2019, and the short-term and long-term liabilities were $1.8 million and $19.2 million , respectively. The following table presents the weighted average remaining lease term and discount rate information related to the Company's operating and finance leases: December 28, 2019 Operating Leases Finance Lease Weighted average remaining lease term 6.09 8.39 Weighted average discount rate 1.93 % 5.1 % The following table provides information related to the Company’s operating and finance leases: Three Months Ended December 28, 2019 Operating lease cost (a) $ 7.0 Finance lease cost - amortization of right-of-use assets $ 0.3 Finance lease cost - interest cost $ 0.3 Cash paid for amounts included in the measurement of lease liabilities: Operating cash flows from finance leases $ 0.3 Operating cash flows from operating leases 5.9 Financing cash flows from finance leases $ 0.4 Total cash paid for amounts included in the measurement of lease liabilities $ 6.6 ROU assets arising from entering into new operating lease obligations $ 1.4 (a) Includes short-term lease expense and variable lease costs, which were immaterial in the three months ended December 28, 2019. During the three months ended December 28, 2019, the non-cash impact of remeasuring the Company's right-of-use assets and operating lease liabilities was $2.4 million . The following table presents the future minimum lease payments under non-cancellable operating lease liabilities and finance lease as of December 28, 2019 : Fiscal Year Operating Leases Finance Lease 2020 remaining $ 17.8 $ 2.1 2021 22.2 2.8 2022 17.3 3.0 2023 10.7 3.0 2024 8.7 3.0 Thereafter 24.0 11.5 Total future minimum lease payments 100.7 25.4 Less: imputed interest (6.2 ) (4.8 ) Present value of lease liabilities $ 94.5 $ 20.6 Lessor Activity - Leases where Hologic is the Lessor Certain assets, primarily diagnostics instruments, are leased to customers under contractual arrangements that typically include an operating or sales-type lease as well as performance obligations for reagents and other consumables. These contractual arrangements are subject to termination provisions which are evaluated in determining the lease term for lease accounting purposes. Sales-type leases are not significant. Contract terms vary by customer and may include options to terminate the contract or options to extend the contract. Where instruments are provided under operating lease arrangements, some portion or the entire lease revenue may be variable and subject to subsequent non-lease component (e.g., reagent) sales. The allocation of revenue between the lease and non-lease components is based on stand-alone selling prices. Lease revenue represented approximately 3%
Leases	Leases Lessee Activity - Leases where Hologic is the Lessee The majority of the Company's facilities are occupied under operating lease arrangements with various expiration dates through 2035, some of which include options to extend the life of the lease, and some of which include options to terminate the lease within one year . The Company has operating leases for office space, land, warehouse and manufacturing space, vehicles and certain equipment. Leases with an initial term of 12 months or less are generally not recorded on the balance sheet and expense for these leases is recognized on a straight-line basis over the lease term. For leases executed in fiscal 2020 and later, the Company accounts for the lease components and the non-lease components as a single lease component. The Company's leases have remaining lease terms of one year to approximately 15 years , some of which may include options to extend the leases for up to 20 years and some include options to terminate early. These options have been included in the determination of the lease liability when it is reasonably certain that the option will be exercised. The Company does not have any leases that include residual value guarantees. The Company determines whether an arrangement is or contains a lease based on the unique facts and circumstances present at the inception of an arrangement. The right-of-use assets and related liabilities for operating leases are included in other assets, accrued expenses, and other long-term liabilities in the consolidated balance sheet as of December 28, 2019. As a result of the Cynosure acquisition, the Company has a finance lease for the facility that was previously Cynosure's U.S. headquarters. This lease was recorded as a capital lease under ASC 840 as of September 28, 2019. The right-of-use asset for the finance lease is included in property, plant and equipment, and the short-term and long-term liability are presented separately in the consolidated balance sheet as of December 28, 2019. Right-of-use assets represent the Company's right to use an underlying asset for the lease term and lease liabilities represent the Company's obligation to make lease payments arising from the lease contract. Operating lease liabilities and their corresponding right-of-use assets are recorded based on the present value of fixed lease payments over the expected lease term. The interest rate implicit in lease contracts is typically not readily determinable. As such, the Company utilizes the appropriate incremental borrowing rate, which is the rate incurred to borrow on a collateralized basis over a similar term at an amount equal to the lease payments in a similar economic environment. The weighted average discount rate utilized on the Company's operating and finance lease liabilities as of December 28, 2019 was 2.57% . The following table presents supplemental balance sheet information related to the Company's operating and finance leases: December 28, 2019 Balance Sheet Location Operating Leases Finance Lease Assets Lease right-of-use assets Other assets $ 89.6 $ — Lease right-of-use assets Property, plant and equipment $ — 9.9 Liabilities Operating lease liabilities (current) Accrued expenses $ 22.2 $ — Finance lease liabilities (current) Finance lease obligations - short term $ — $ 1.8 Operating lease liabilities (non-current) Other long-term liabilities $ 72.3 $ — Finance lease liabilities (non-current) Finance lease obligations - long term $ — $ 18.8 The finance lease was previously recorded as a capital lease in the consolidated balance at September 28, 2019, and the short-term and long-term liabilities were $1.8 million and $19.2 million , respectively. The following table presents the weighted average remaining lease term and discount rate information related to the Company's operating and finance leases: December 28, 2019 Operating Leases Finance Lease Weighted average remaining lease term 6.09 8.39 Weighted average discount rate 1.93 % 5.1 % The following table provides information related to the Company’s operating and finance leases: Three Months Ended December 28, 2019 Operating lease cost (a) $ 7.0 Finance lease cost - amortization of right-of-use assets $ 0.3 Finance lease cost - interest cost $ 0.3 Cash paid for amounts included in the measurement of lease liabilities: Operating cash flows from finance leases $ 0.3 Operating cash flows from operating leases 5.9 Financing cash flows from finance leases $ 0.4 Total cash paid for amounts included in the measurement of lease liabilities $ 6.6 ROU assets arising from entering into new operating lease obligations $ 1.4 (a) Includes short-term lease expense and variable lease costs, which were immaterial in the three months ended December 28, 2019. During the three months ended December 28, 2019, the non-cash impact of remeasuring the Company's right-of-use assets and operating lease liabilities was $2.4 million . The following table presents the future minimum lease payments under non-cancellable operating lease liabilities and finance lease as of December 28, 2019 : Fiscal Year Operating Leases Finance Lease 2020 remaining $ 17.8 $ 2.1 2021 22.2 2.8 2022 17.3 3.0 2023 10.7 3.0 2024 8.7 3.0 Thereafter 24.0 11.5 Total future minimum lease payments 100.7 25.4 Less: imputed interest (6.2 ) (4.8 ) Present value of lease liabilities $ 94.5 $ 20.6 Lessor Activity - Leases where Hologic is the Lessor Certain assets, primarily diagnostics instruments, are leased to customers under contractual arrangements that typically include an operating or sales-type lease as well as performance obligations for reagents and other consumables. These contractual arrangements are subject to termination provisions which are evaluated in determining the lease term for lease accounting purposes. Sales-type leases are not significant. Contract terms vary by customer and may include options to terminate the contract or options to extend the contract. Where instruments are provided under operating lease arrangements, some portion or the entire lease revenue may be variable and subject to subsequent non-lease component (e.g., reagent) sales. The allocation of revenue between the lease and non-lease components is based on stand-alone selling prices. Lease revenue represented approximately 3%
Leases	Leases Lessee Activity - Leases where Hologic is the Lessee The majority of the Company's facilities are occupied under operating lease arrangements with various expiration dates through 2035, some of which include options to extend the life of the lease, and some of which include options to terminate the lease within one year . The Company has operating leases for office space, land, warehouse and manufacturing space, vehicles and certain equipment. Leases with an initial term of 12 months or less are generally not recorded on the balance sheet and expense for these leases is recognized on a straight-line basis over the lease term. For leases executed in fiscal 2020 and later, the Company accounts for the lease components and the non-lease components as a single lease component. The Company's leases have remaining lease terms of one year to approximately 15 years , some of which may include options to extend the leases for up to 20 years and some include options to terminate early. These options have been included in the determination of the lease liability when it is reasonably certain that the option will be exercised. The Company does not have any leases that include residual value guarantees. The Company determines whether an arrangement is or contains a lease based on the unique facts and circumstances present at the inception of an arrangement. The right-of-use assets and related liabilities for operating leases are included in other assets, accrued expenses, and other long-term liabilities in the consolidated balance sheet as of December 28, 2019. As a result of the Cynosure acquisition, the Company has a finance lease for the facility that was previously Cynosure's U.S. headquarters. This lease was recorded as a capital lease under ASC 840 as of September 28, 2019. The right-of-use asset for the finance lease is included in property, plant and equipment, and the short-term and long-term liability are presented separately in the consolidated balance sheet as of December 28, 2019. Right-of-use assets represent the Company's right to use an underlying asset for the lease term and lease liabilities represent the Company's obligation to make lease payments arising from the lease contract. Operating lease liabilities and their corresponding right-of-use assets are recorded based on the present value of fixed lease payments over the expected lease term. The interest rate implicit in lease contracts is typically not readily determinable. As such, the Company utilizes the appropriate incremental borrowing rate, which is the rate incurred to borrow on a collateralized basis over a similar term at an amount equal to the lease payments in a similar economic environment. The weighted average discount rate utilized on the Company's operating and finance lease liabilities as of December 28, 2019 was 2.57% . The following table presents supplemental balance sheet information related to the Company's operating and finance leases: December 28, 2019 Balance Sheet Location Operating Leases Finance Lease Assets Lease right-of-use assets Other assets $ 89.6 $ — Lease right-of-use assets Property, plant and equipment $ — 9.9 Liabilities Operating lease liabilities (current) Accrued expenses $ 22.2 $ — Finance lease liabilities (current) Finance lease obligations - short term $ — $ 1.8 Operating lease liabilities (non-current) Other long-term liabilities $ 72.3 $ — Finance lease liabilities (non-current) Finance lease obligations - long term $ — $ 18.8 The finance lease was previously recorded as a capital lease in the consolidated balance at September 28, 2019, and the short-term and long-term liabilities were $1.8 million and $19.2 million , respectively. The following table presents the weighted average remaining lease term and discount rate information related to the Company's operating and finance leases: December 28, 2019 Operating Leases Finance Lease Weighted average remaining lease term 6.09 8.39 Weighted average discount rate 1.93 % 5.1 % The following table provides information related to the Company’s operating and finance leases: Three Months Ended December 28, 2019 Operating lease cost (a) $ 7.0 Finance lease cost - amortization of right-of-use assets $ 0.3 Finance lease cost - interest cost $ 0.3 Cash paid for amounts included in the measurement of lease liabilities: Operating cash flows from finance leases $ 0.3 Operating cash flows from operating leases 5.9 Financing cash flows from finance leases $ 0.4 Total cash paid for amounts included in the measurement of lease liabilities $ 6.6 ROU assets arising from entering into new operating lease obligations $ 1.4 (a) Includes short-term lease expense and variable lease costs, which were immaterial in the three months ended December 28, 2019. During the three months ended December 28, 2019, the non-cash impact of remeasuring the Company's right-of-use assets and operating lease liabilities was $2.4 million . The following table presents the future minimum lease payments under non-cancellable operating lease liabilities and finance lease as of December 28, 2019 : Fiscal Year Operating Leases Finance Lease 2020 remaining $ 17.8 $ 2.1 2021 22.2 2.8 2022 17.3 3.0 2023 10.7 3.0 2024 8.7 3.0 Thereafter 24.0 11.5 Total future minimum lease payments 100.7 25.4 Less: imputed interest (6.2 ) (4.8 ) Present value of lease liabilities $ 94.5 $ 20.6 Lessor Activity - Leases where Hologic is the Lessor Certain assets, primarily diagnostics instruments, are leased to customers under contractual arrangements that typically include an operating or sales-type lease as well as performance obligations for reagents and other consumables. These contractual arrangements are subject to termination provisions which are evaluated in determining the lease term for lease accounting purposes. Sales-type leases are not significant. Contract terms vary by customer and may include options to terminate the contract or options to extend the contract. Where instruments are provided under operating lease arrangements, some portion or the entire lease revenue may be variable and subject to subsequent non-lease component (e.g., reagent) sales. The allocation of revenue between the lease and non-lease components is based on stand-alone selling prices. Lease revenue represented approximately 3%

Fair Value Measurements

Fair Value Measurements	3 Months Ended
	Dec. 28, 2019
Fair Value Disclosures [Abstract]
Fair Value Measurement and Measurement Inputs, Recurring and Nonrecurring [Text Block]	Fair Value Measurements Assets/Liabilities Measured and Recorded at Fair Value on a Recurring Basis The Company has investments in derivative instruments consisting of interest rate caps, interest rate swaps and foreign currency contracts, which are valued using analyses obtained from independent third party valuation specialists based on market observable inputs, representing Level 2 assets. The fair values of the Company's interest rate caps, interest rate swaps, forward foreign currency contracts and foreign currency option contracts represent the estimated amounts the Company would receive or pay to terminate the contracts. Refer to Note 8 for further discussion and information on the interest rate caps and foreign currency contracts. Assets and liabilities measured and recorded at fair value on a recurring basis consisted of the following at December 28, 2019 : Fair Value at Reporting Date Using Balance as of December 28, 2019 Quoted Prices in Active Market for Identical Assets (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) Assets: Interest rate swaps - derivative $ 10.4 $ — $ 10.4 $ — Foreign currency option contracts 0.3 — 0.3 — Forward foreign currency contracts 0.5 — 0.5 — Total $ 11.2 $ — $ 11.2 $ — Liabilities: Contingent consideration $ 9.3 $ — $ — $ 9.3 Forward foreign currency contracts 1.2 — 1.2 — Total $ 10.5 $ — $ 1.2 $ 9.3 Assets Measured and Recorded at Fair Value on a Recurring Basis The Company has contingent consideration liabilities related to its Emsor S.A. and Faxitron Bioptics, LLC acquisitions. The remeasurement of these liabilities in the first quarter of fiscal 2020 was insignificant. The Company paid these contingent consideration liabilities in January 2020. Assets Measured and Recorded at Fair Value on a Nonrecurring Basis The Company remeasures the fair value of certain assets and liabilities upon the occurrence of certain events. Such assets consist of equity investments and long-lived assets, including property, plant and equipment, intangible assets and goodwill. There were no such remeasurements for equity investments in the three months ended December 28, 2019 and December 29, 2018 . During the first quarter of fiscal 2020, the Company's Medical Aesthetics division met the criteria to be classified as assets-held-for sale and the Company recorded a $30.2 million loss to record the asset group at its fair value less costs to sell. This is a level 1 measurement. See Note 6 for additional information. Disclosure of Fair Value of Financial Instruments The Company’s financial instruments mainly consist of cash and cash equivalents, accounts receivable, equity investments, interest rate caps, interest rate swaps, forward foreign currency contracts, foreign currency option contracts, insurance contracts, accounts payable and debt obligations. The carrying amounts of the Company’s cash equivalents, accounts receivable and accounts payable approximate their fair value due to the short-term nature of these instruments. The Company’s interest rate caps, interest rate swaps, forward foreign currency contracts and foreign currency option contracts are recorded at fair value. The carrying amount of the insurance contracts is recorded at the cash surrender value, as required by GAAP, which approximates fair value. The Company believes the carrying amounts of its equity investments approximate fair value. Amounts outstanding under the Company’s 2018 Credit Agreement (as defined below) and Securitization Program of $1.5 billion and $250.0 million aggregate principal, respectively, as of December 28, 2019 are subject to variable interest rates, which are based on current market rates, and as such, the Company believes the carrying amount of these obligations approximates fair value. The Company’s 2025 Senior Notes and 2028 Senior Notes had fair values of $983.4 million and $424.0 million , respectively, as of December 28, 2019 based on their trading prices, representing Level 1 measurements. Refer to Note 7 for the carrying amounts of the various components of the Company’s debt.

Business Combinations

Business Combinations	3 Months Ended
	Dec. 28, 2019
Business Combinations [Abstract]
Business Combinations	Business Combinations Focal Therapeutics On October 1, 2018, the Company completed the acquisition of Focal Therapeutics, Inc. ("Focal") for a purchase price of $120.1 million , which included hold-backs of $14.0 million payable up to one year from the date of acquisition. In the second quarter of fiscal 2019, $1.5 million of the hold-back was paid, and the remaining $12.5 million was paid on October 1, 2019. Focal, headquartered in California, manufactures and markets its BioZorb marker, which is an implantable three-dimensional marker that helps clinicians overcome certain challenges in breast conserving surgery. The total purchase price was allocated to Focal's tangible and identifiable intangible assets and liabilities based on the estimated fair values of those assets as of October 1, 2018, as set forth below: Cash $ 2.2 Accounts receivable 2.0 Inventory 7.9 Other assets 0.5 Accounts payable and accrued expenses (5.6 ) Long-term debt (2.5 ) Identifiable intangible assets: Developed technology 83.1 In-process research and development 11.4 Trade names 2.7 Deferred income taxes, net (12.7 ) Goodwill 31.1 Purchase Price $ 120.1 In performing the purchase price allocation, the Company considered, among other factors, the intended future use of acquired assets, analysis of historical financial performance and estimates of future performance of Focal's business. As part of the purchase price allocation, the Company determined the identifiable intangible assets were developed technology, in-process research and development ("IPR&D"), and trade names. The fair value of the intangible assets was estimated using the income approach, and the cash flow projections were discounted using rates ranging from 15.5% to 16.5% . The cash flows were based on estimates used to price the transaction, and the discount rates applied were benchmarked with reference to the implied rate of return from the transaction model and the weighted average cost of capital. The weighted average life of developed technology and trade names was 11 years and 13 years, respectively. The calculation of the excess of the purchase price over the estimated fair value of the tangible net assets and intangible assets acquired was recorded to goodwill. The factors contributing to the recognition of the amount of goodwill were based on synergistic benefits that are expected to be realized from this acquisition. Benefits include the expectation of broadening the Company's Breast Health portfolio of products and technology. None of the goodwill is expected to be deductible for income tax purposes. SuperSonic Imagine On August 1, 2019, the Company purchased 46% of the outstanding shares of SuperSonic Imagine ("SSI") for $18.2 million . SSI is a public company located in Aix-en-Provence, France that manufactures and markets ultrasound medical imaging equipment. In September 2019, the Company launched a cash tender offer to acquire the remaining outstanding shares for a price of €1.50 per share in cash. The Company determined that SSI was a Variable Interest Entity (“VIE”) but it was not the primary beneficiary as it was not a party to the initial design of the entity nor did it have control over SSI's operations until November 21, 2019 when the Company's ownership of SSI's voting stock exceeded 50% . Accordingly, the Company initially accounted for this investment under the equity method of accounting and included its proportionate share of SSI's net loss of $3.3 million for the two months ended September 28, 2019 within Other income, net. On November 21, 2019, the Company acquired an additional 7.6 million shares of SSI for $12.6 million . As a result, the Company owned approximately 78% of the outstanding shares of SSI at November 21, 2019 and controlled SSI's voting interest and operations. The Company performed purchase accounting as of November 21, 2019 and beginning on that date the financial results of SSI are included within the Company's consolidated financial statements. The Company remeasured the initial investment of 46% of the outstanding shares of SSI to its fair value at the acquisition date, resulting in a gain of $3.2 million in the first quarter of fiscal 2020. The total purchase price was $69.3 million , which consisted of $17.9 million for the equity method investment in SSI, $12.6 million for shares acquired on November 21, 2019, $30.2 million for loans the Company provided to SSI prior to the acquisition that are considered forgiven, and $8.6 million representing the fair value of the noncontrolling interest as of November 21, 2019. The total purchase price was allocated to SSI's preliminary tangible and identifiable intangible assets and liabilities based on the estimated fair values of those assets as of November 21, 2019, as set forth below. The preliminary purchase price allocation is as follows: Cash $ 2.6 Accounts receivable 7.1 Inventory 10.0 Property, plant and equipment 6.5 Other assets 4.4 Accounts payable and accrued expenses (13.0 ) Deferred revenue (1.8 ) Short and long-term debt (8.8 ) Other liabilities (3.8 ) Identifiable intangible assets: — Developed technology 33.2 Customer relationships 3.1 Trade names 3.5 Deferred income taxes, net (2.4 ) Goodwill 28.7 Purchase Price $ 69.3 In performing the preliminary purchase price allocation, the Company considered, among other factors, the intended future use of acquired assets, analysis of historical financial performance and estimates of future performance of SSI's business. The Company has not yet obtained all of the information related to the fair value of the acquired assets and liabilities, primarily taxes and the valuation of intangible assets, to finalize the purchase price allocation. As part of the preliminary purchase price allocation, the Company has determined the identifiable intangible assets are developed technology, customer relationships, and trade names. The preliminary fair value of the intangible assets has been estimated using the income approach, and the cash flow projections were discounted using a 12.0% rate. The cash flows are based on estimates used to price the transaction, and the discount rates applied were benchmarked with reference to the implied rate of return from the transaction model and the weighted average cost of capital. The weighted average life for the developed technology is 9 years , customer relationships is 9 years and for trade names it is 8.3 years . The preliminary calculation of the excess of the purchase price over the estimated fair value of the tangible net assets and intangible assets acquired was recorded to goodwill. The factors contributing to the recognition of the preliminary amount of goodwill are based on synergistic benefits of SSI's products being complementary to Breast Health's 3D mammography systems and using the Company's existing U.S. sales force as SSI's presence in the U.S. is limited. None of the goodwill is expected to be deductible for income tax purposes.

Disposition

Disposition	3 Months Ended
	Dec. 28, 2019
Discontinued Operations and Disposal Groups [Abstract]
Dispositions	Disposition Sale of Medical Aesthetics - Assets Held-for-Sale On November 20, 2019, the Company entered into a definitive agreement to sell its Medical Aesthetics business to Clayton Dubilier & Rice ("CD&R") for a sales price of $205.0 million in cash, less certain adjustments. The sale was completed on December 30, 2019, and the Company received cash proceeds of $153.4 million . The sale price remains subject to adjustment upon finalization pursuant to the terms of the definitive agreement. The Company has agreed to provide certain transition services for three to fifteen months, depending on the nature of the service. As a result of this transaction, the Medical Aesthetics asset group was designated as assets held-for-sale in the first quarter of fiscal 2020. Pursuant to ASC 360, asset groups under this designation are required to be recorded at fair value less costs to sell. Based on the terms in the agreement of the sales price and formula for net working capital and related adjustments, its estimate of the fair value for transition services which must be carved out of the sale proceeds, and liabilities the Company will retain or for which it has agreed to indemnify CD&R, the Company recorded an impairment charge of $30.2 million in the first quarter of fiscal 2020. The impairment charge was allocated to Medical Aesthetics long-lived assets, of which $25.8 million was allocated to cost of product revenues and $4.4 million to operating expenses. Assets held-for sale comprise the following as of December 28, 2019: Assets: December 28, 2019 Cash $ 10.7 Accounts Receivable 59.6 Inventory 90.6 Prepaid expenses and other current assets 7.7 Property, plant, and equipment 4.0 Intangible assets 28.2 Other assets 9.8 Total assets held-for-sale $ 210.6 Liabilities: Accounts payable $ 12.3 Accrued expenses 49.0 Deferred revenue 16.6 Total liabilities held-for-sale $ 77.9 The Company has determined that this disposal did not qualify as a discontinued operation as the sale of the Medical Aesthetics business was deemed to not be a strategic shift having or will have a major effect on the Company's operations and financial results.

Borrowings and Credit Arrangeme

Borrowings and Credit Arrangements	3 Months Ended
	Dec. 28, 2019
Debt Disclosure [Abstract]
Borrowings and Credit Arrangements	Borrowings and Credit Arrangements The Company’s borrowings consisted of the following: December 28, September 28, Current debt obligations, net of debt discount and deferred issuance costs: Term Loan $ 46.8 $ 37.4 Securitization Program 250.0 234.0 Debt assumed from SSI acquisition 5.4 — Total current debt obligations $ 302.2 $ 271.4 Long-term debt obligations, net of debt discount and deferred issuance costs: Term Loan 1,434.3 1,452.4 Debt assumed from SSI acquisition 3.2 — 2025 Senior Notes 937.8 937.3 2028 Senior Notes 394.1 393.9 Total long-term debt obligations $ 2,769.4 $ 2,783.6 Total debt obligations $ 3,071.6 $ 3,055.0 2018 Amended and Restated Credit Agreement On December 17, 2018, the Company and certain of its subsidiaries refinanced its term loan and revolving credit facility by entering into an Amended and Restated Credit and Guaranty Agreement as of December 17, 2018 (the "2018 Credit Agreement") with Bank of America, N.A. in its capacity as Administrative Agent, Swing Line Lender and L/C Issuer, and certain other lenders. The 2018 Credit Agreement amended and restated the Company's prior credit and guaranty agreement dated as of October 3, 2017 (the "2017 Credit Agreement"). The borrowings of the 2018 Amended Term Loan bear interest at an annual rate equal to the Eurocurrency Rate (i.e., the LIBOR rate) plus an Applicable Rate, which was equal to 1.250% as of December 28, 2019. The borrowings of the 2018 Amended Revolver bear interest at a rate equal to the LIBOR Daily Floating Rate plus an Applicable Rate equal to 1.250% . Pursuant to ASC 470, Debt (ASC 470), the accounting related to entering into the 2018 Credit Agreement and using the proceeds to pay off the 2017 Credit Agreement was evaluated on a creditor-by-creditor basis to determine whether each transaction should be accounted for as a modification or extinguishment. Certain creditors under the 2017 Credit Agreement did not participate in this refinancing transaction and ceased being creditors of the Company. As a result, the Company recorded a debt extinguishment loss of $0.8 million in the first quarter of fiscal 2019. For the remainder of the creditors, this transaction was accounted for as a modification because on a creditor-by-creditor basis the present value of the cash flows between the two debt instruments before and after the transaction was less than 10% . Pursuant to ASC 470, subtopic 50-40, third-party costs of $0.8 million related to this transaction were recorded as interest expense and $1.9 million was recorded as a reduction to debt representing deferred issuance costs and debt discount for fees paid directly to the lenders. Interest expense, weighted average interest rate, and interest rate at the end of period under the Credit Agreements were as follows: Three Months Ended December 28, 2019 December 29, 2018 Interest expense $ 13.6 $ 18.0 Weighted average interest rate 3.11 % 3.82 % Interest rate at end of period 3.04 % 3.88 % The 2018 Credit Agreement contains two financial covenants; a total leverage ratio and an interest coverage ratio, both of which are measured as of the last day of each fiscal quarter. These terms, and calculations thereof, are defined in further detail in the 2018 Credit Agreement. As of December 28, 2019, the Company was in compliance with these covenants. Senior Notes On October 10, 2017, the Company completed a private placement of $350 million aggregate principal amount of its 4.375% Senior Notes due 2025 (the "2025 Senior Notes") at an offering price of 100% of the aggregate principal amount of the 2025 Senior Notes. On January 19, 2018, the Company completed a private placement of $1.0 billion aggregate principal amount of senior notes, allocated between (i) an additional $600 million aggregate principal amounts of its 2025 Senior Notes pursuant to a supplement to the indenture governing the Company's existing 2025 Senior Notes at an offering price of 100% of the aggregate principal amount of the 2025 Senior Notes and (ii) $400 million aggregate principal amounts of its 4.625% Senior Notes due 2028 (the "2028 Senior Notes") at an offering price of 100% of the aggregate principal amount of the 2028 Senior Notes. 2025 Senior Notes The total aggregate principal balance of 2025 Senior Notes is $950 million . The 2025 Senior Notes are general senior unsecured obligations of the Company and are guaranteed on a senior unsecured basis by certain domestic subsidiaries and mature on October 15, 2025. 2028 Senior Notes The aggregate principal balance of the 2028 Senior Notes is $400 million . The 2028 Senior Notes are general senior unsecured obligations of the Company and are guaranteed on a senior unsecured basis by certain domestic subsidiaries and mature on February 1, 2028. Interest expense for the 2028 Senior Notes and 2025 Senior Notes is as follows: Three Months Ended December 28, 2019 December 29, 2018 Interest Rate Interest Expense Interest Expense 2028 Senior Notes 4.625 % $ 4.8 $ 4.8 2025 Senior Notes 4.375 % 10.9 10.9 Total $ 15.7 $ 15.7

Derivatives

Derivatives	3 Months Ended
	Dec. 28, 2019
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Derivatives	Derivatives Interest Rate Cap - Cash Flow Hedge The Company is exposed to certain risks arising from both its business operations and economic conditions. The Company manages its exposure to some of its interest rate risk through the use of interest rate caps, which are derivative financial instruments. The Company does not use derivatives for speculative purposes. For a derivative that is designated as a cash flow hedge, changes in the fair value of the derivative are recognized in accumulated other comprehensive income ("AOCI") to the extent the derivative is effective at offsetting the changes in the cash flows being hedged until the hedged item affects earnings. To the extent there is any hedge ineffectiveness, changes in fair value relating to the ineffective portion are immediately recognized in earnings in other income (expense), net in the Consolidated Statements of Operations. During fiscal 2018, the Company entered into separate interest rate cap agreements with multiple counter-parties to help mitigate the interest rate volatility associated with the variable interest rate on amounts borrowed under the term loan feature of its credit facilities (see Note 7). Interest rate cap agreements provide the right to receive cash if the reference interest rate rises above a contractual rate. The aggregate premium paid for these interest rate cap agreements was $3.7 million , which was the initial fair value of the instruments recorded in the Company's financial statements. During fiscal 2019, the Company entered into additional separate interest rate cap agreements with multiple counter-parties to extend the expiration date of its hedges by an additional year. The aggregate premium paid for these interest cap agreements was $1.5 million , which was the initial fair value of the instruments recorded in the Company’s financial statements. The critical terms of the interest rate caps were designed to mirror the terms of the Company’s LIBOR-based borrowings under its Credit Agreement, that has been amended multiple times, and therefore are highly effective at offsetting the cash flows being hedged. The Company designated these derivatives as cash flow hedges of the variability of the LIBOR-based interest payments on $1.0 billion of principal, which ended on December 27, 2019 for the contracts entered into in fiscal 2018, and which will end on December 23, 2020 for the interest rate cap agreements entered into in fiscal 2019. As of December 28, 2019 , the Company determined that the existence of hedge ineffectiveness, if any, was immaterial, and all changes in the fair value of the interest rate caps were recorded in the Consolidated Statements of Comprehensive Income (Loss) as a component of AOCI. During the three months ended December 28, 2019 and December 29, 2018 , the Company reclassified $1.3 million and $0.7 million , respectively from AOCI to the Consolidated Statements of Income related to the interest rate cap agreements. The Company expects to similarly reclassify a loss of approximately $1.5 million from AOCI to the Consolidated Statements of Income in the next twelve months. The aggregate fair value of these interest rate caps was $0.0 million and $0.1 million at December 28, 2019 and September 28, 2019 , respectively, and is included in Prepaid expenses and other current assets on the Company’s Consolidated Balance Sheet. Refer to Note 4 “Fair Value Measurements” above for related fair value disclosures. Interest Rate Swap - Cash Flow Hedge In fiscal 2019, in order to hedge a portion of its variable rate debt, the Company entered into an interest rate swap contract with an effective date of December 23, 2020 and a termination date of December 17, 2023. The initial notional amount of this swap was $1.0 billion . The interest rate swap effectively fixes the LIBOR component of the variable interest rate on $1.0 billion of the notional amount under the 2018 Credit Agreement at 1.23% . The critical terms of the interest rate swap are designed to mirror the terms of the Company’s LIBOR-based borrowings under its credit agreement and therefore are highly effective at offsetting the cash flows being hedged. The Company designated this derivative as cash flow hedges of the variability of the LIBOR-based interest payments on $1.0 billion of principal. Therefore, changes in the fair value of the swap are recorded in AOCI. The fair value of this derivative was $10.4 million as of December 28, 2019 . Forward Foreign Currency Contracts and Foreign Currency Option Contracts The Company enters into forward foreign currency exchange contracts and foreign currency option contracts to mitigate certain operational exposures from the impact of changes in foreign currency exchange rates. Such exposures result from the portion of the Company's operations that are denominated in currencies other than the U.S. dollar, primarily the Euro, the UK Pound, the Australian dollar, the Canadian dollar, the Chinese Yuan and the Japanese Yen. These foreign currency exchange contracts are entered into to support transactions made in the ordinary course of business and are not speculative in nature. The contracts are generally for periods of one year or less. The Company did not elect hedge accounting for these forward foreign currency contracts and foreign currency option contracts; however, the Company may seek to apply hedge accounting in future scenarios. The change in the fair value of these contracts is recognized directly in earnings as a component of other income (expense), net. During the three months ended December 28, 2019 and December 29, 2018, for the forward foreign currency exchange contracts the Company recorded net realized gains of $0.0 million and $1.7 million , respectively, from settling forward foreign currency exchange contracts and net unrealized losses of $1.5 million and net unrealized gains of $3.4 million , respectively, on the mark-to-market for its outstanding forward foreign currency contracts. During the three months ended December 28, 2019 , for the foreign currency option contracts the Company recorded net unrealized losses of $1.5 million on outstanding option contracts. As of December 28, 2019 , the Company had outstanding forward foreign currency contracts that were not designated for hedge accounting and were used to hedge fluctuations in the U.S. dollar of forecasted transactions denominated in the Australian dollar, Canadian Dollar, Chinese Yuan and Japanese Yen with an aggregate notional amount of $77.0 million . As of December 28, 2019 , the Company had outstanding foreign currency option contracts that were not designated for hedge accounting and are used to hedge fluctuations in the U.S. dollar of forecasted transactions denominated in the Euro and UK Pound with a notional amount of $124.2 million . Financial Instrument Presentation The table below presents the fair value of the Company's derivative financial instruments as well as their classification on the balance sheet as of December 28, 2019 : Balance Sheet Location December 28, 2019 September 28, 2019 Assets: Derivative instruments designated as a cash flow hedge: Interest rate cap agreements Prepaid expenses and other current assets $ — $ 0.1 Interest rate swap contract Other assets 10.4 4.7 $ 10.4 $ 4.8 Derivatives not designated as hedging instruments: Forward foreign currency contracts Prepaid expenses and other current assets $ 0.5 $ 0.9 Foreign currency option contracts Prepaid expenses and other current assets 0.3 2.0 $ 0.8 $ 2.9 Liabilities: Derivatives not designated as hedging instruments: Forward foreign currency contracts Accrued expenses $ 1.2 $ 0.1 The following table presents the unrealized gain (loss) recognized in AOCI related to the interest rate caps and interest rate swap for the following reporting periods: Three Months Ended December 28, 2019 December 29, 2018 Amount of gain (loss) recognized in other comprehensive income, net of taxes: Interest rate swap $ 4.3 $ — Interest rate cap agreements (0.3 ) (3.9 ) Total $ 4.0 $ (3.9 ) The following table presents the adjustment to fair value (realized and unrealized) recorded within the Consolidated Statements of Income for derivative instruments for which the Company did not elect hedge accounting: Derivatives not classified as hedging instruments Amount of (Loss) Gain Recognized in Income Three Months Ended December 28, 2019 Three Months Ended December 29, 2018 Forward foreign currency contracts $ (1.5 ) $ 5.1 Foreign currency option contracts (1.7 ) — Total $ (3.2 ) $ 5.1

Commitments and Contingencies

Commitments and Contingencies	3 Months Ended
	Dec. 28, 2019
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	Commitments and Contingencies Litigation and Related Matters On November 6, 2015, the Company filed a suit against Minerva Surgical, Inc. (“Minerva”) in the United States District Court for the District of Delaware, alleging that Minerva’s endometrial ablation device infringes U.S. Patent 6,872,183 (the '183 patent), U.S. Patent 8,998,898 and U.S. Patent 9,095,348 (the '348 patent). On January 25, 2016, the Company amended the complaint to include claims against Minerva for unfair competition, deceptive trade practices and tortious interference with business relationships. On February 5, 2016, the Company filed a second amended complaint to additionally allege that Minerva’s endometrial ablation device infringes U.S. Patent 9,247,989 (the '989 patent). On March 4, 2016, Minerva filed an answer and counterclaims against the Company, seeking declaratory judgment on the Company’s claims and asserting claims against the Company for unfair competition, deceptive trade practices, interference with contractual relationships, breach of contract and trade libel. On June 2, 2016, the Court denied the Company’s motion for a preliminary injunction on its patent claims and denied Minerva’s request for preliminary injunction related to the Company’s alleged false and deceptive statements regarding the Minerva product. On June 28, 2018, the Court granted the Company's summary judgment motions on infringement and no invalidity with respect to the ‘183 and ‘348 patents. The Court also granted the Company’s motion for summary judgment on assignor estoppel, which bars Minerva’s invalidity defenses or any reliance on collateral findings regarding invalidity from inter partes review proceedings. The Court also denied all of Minerva’s defenses, including its motions for summary judgment on invalidity, non-infringement, no willfulness, and no unfair competition. On July 27, 2018, after a two-week trial, a jury returned a verdict that: (1) awarded the Company $4.8 million in damages for Minerva’s infringement; (2) found that Minerva’s infringement was not willful; and (3) found for the Company regarding Minerva’s counterclaims. Damages will continue to accrue until Minerva ceases its infringing conduct. On May 2, 2019, the Court issued rulings that denied the parties' post-trial motions, including the Company's motion for a permanent injunction seeking to prohibit Minerva from selling infringing devices. Both parties appealed the Court's rulings regarding the post-trial motions, and oral argument for the appeals was held on December 4, 2019. On March 4, 2016, Minerva filed two petitions at the USPTO for inter partes review of the '348 patent. On September 12, 2016, the PTAB declined both petitions to review patentability of the '348 patent. On April 11, 2016, Minerva filed a petition for inter partes review of the '183 patent. On October 6, 2016, the PTAB granted the petition and instituted a review of the '183 patent. On December 15, 2017, the PTAB issued a final written decision invalidating all claims of the ‘183 patent. On February 9, 2018 the Company appealed this decision to the United States Court of Appeals for the Federal Circuit ("Court of Appeals"). On April 19, 2019, the Court of Appeals affirmed the PTAB's final written decision regarding the '183 patent. On July 16, 2019, the Court of Appeals denied the Company’s petition for rehearing in the appeal regarding the '183 patent. On April 11, 2017, Minerva filed suit against the Company and Cytyc Surgical Products, LLC (“Cytyc”) in the United States District Court for the Northern District of California alleging that the Company’s and Cytyc’s NovaSure ADVANCED endometrial ablation device infringes Minerva’s U.S. patent 9,186,208. Minerva is seeking a preliminary and permanent injunction against the Company and Cytyc from selling this NovaSure device as well as enhanced damages and interest, including lost profits, price erosion and/or royalty. On January 5, 2018, the Court denied Minerva's motion for a preliminary injunction. On February 2, 2018, at the parties’ joint request, this action was transferred to the District of Delaware. On March 26, 2019, the Magistrate Judge issued a claims construction ruling regarding the disputed terms in the patent, which the District Court Judge adopted in all respects on October 21, 2019. Trial is scheduled for July 20, 2020. At this time, based on available information regarding this litigation, the Company is unable to reasonably assess the ultimate outcome of this case or determine an estimate, or a range of estimates, of potential losses. On February 3, 2017, bioMérieux, S.A. and bioMérieux, Inc. (collectively “bioMérieux”) filed suit against the Company in the United States District Court for the Middle District of North Carolina ("MDNC"), alleging that the Company’s HIV products, including blood screening products previously manufactured by the Company for its former blood screening partner Grifols Diagnostic Solutions Inc. ("Grifols USA"), infringe U.S. Patent Nos. 8,697,352 and 9,074,262. On January 3, 2018, the MDNC Court granted the parties’ consent motion to transfer the case to Delaware. On June 11, 2019, the Court issued a claim construction ruling regarding the disputed terms in the patents. Motions for summary judgment were filed by the parties on September 30, 2019. A hearing on these motions was held on December 18, 2019, and the trial is scheduled to begin on February 18, 2020. The Company filed petitions for inter partes review of the asserted patents on February 6, 2018. The USPTO denied the Company’s petitions for inter partes review in August and September, 2018. The Company filed requests for rehearing of the denial orders, which requests were denied. At this time, based on available information regarding this litigation, the Company is unable to reasonably assess the ultimate outcome of this case or determine an estimate, or range of estimates, of potential losses. On July 27, 2016, plaintiff ARcare, Inc., individually and as putative representative of a purported nationwide class, filed a complaint against Cynosure, Inc. ("Cynosure"). The plaintiff alleges that Cynosure violated the Telephone Consumer Protection Act by: (i) sending fax advertisements that did not comply with statutory and Federal Communications Commission requirements that senders provide recipients with certain information about how to opt out from receiving faxed advertisements in the future; and (ii) sending unsolicited fax advertisements. The complaint sought damages, declaratory and injunctive relief, and attorneys’ fees on behalf of a purported class of all recipients of purported fax advertisements that the plaintiff alleges did not receive an adequate opt-out notice. On September 30, 2016, Cynosure answered the complaint and denied liability. On September 7, 2016, the plaintiff sent a demand letter seeking a class settlement for statutory damages under Massachusetts General Laws, Chapter 93A § 9 (“Chapter 93A”). On October 7, 2016, Cynosure responded denying any liability under Chapter 93A, but offering the plaintiff statutory damages of $25 on an individual basis. In March 2017, Cynosure and ARcare entered into a settlement agreement, subject to court approval, which requires Cynosure to pay settlement compensation of $8.5 million notwithstanding the number of claims filed. If approved, Cynosure would receive a full release from the settlement class concerning the conduct alleged in the complaint. On March 14, 2019, the Court entered an order providing preliminary approval of the settlement. During a hearing on July 11, 2019, the Court requested additional information from the parties in assessing whether to grant final approval of the settlement. The Company will indemnify CD&R for this matter and continues to have $8.5 million accrued for this matter as of December 28, 2019 . The Company is a party to various other legal proceedings and claims arising out of the ordinary course of its business. The Company believes that except for those matters described above there are no other proceedings or claims pending against it the ultimate resolution of which could have a material adverse effect on its financial condition or results of operations. In all cases, at each reporting period, the Company evaluates whether or not a potential loss amount or a potential range of loss is probable and reasonably estimable under ASC 450, Contingencies . Legal costs are expensed as incurred.

Net Income (Loss) Per Share

Net Income (Loss) Per Share	3 Months Ended
	Dec. 28, 2019
Earnings Per Share [Abstract]
Net Income (Loss) Per Share	Net Income Per Share A reconciliation of basic and diluted share amounts is as follows: Three Months Ended December 28, December 29, Basic weighted average common shares outstanding 267,893 270,590 Weighted average common stock equivalents from assumed exercise of stock options and issuance of stock units 1,828 1,782 Diluted weighted average common shares outstanding 269,721 272,372 Weighted-average anti-dilutive shares related to: Outstanding stock options 1,290 3,339 Stock Units 1 4

Stock-Based Compensation

Stock-Based Compensation	3 Months Ended
	Dec. 28, 2019
Share-based Payment Arrangement [Abstract]
Stock-Based Compensation	Stock-Based Compensation The following presents stock-based compensation expense in the Company’s Consolidated Statements of Operations: Three Months Ended December 28, December 29, Cost of revenues $ 2.0 $ 2.0 Research and development 2.4 2.7 Selling and marketing 2.8 2.7 General and administrative 10.9 9.7 $ 18.1 $ 17.1 The Company granted options to purchase 0.8 million and 0.9 million shares of the Company's common stock during the three months ended December 28, 2019 and December 29, 2018 , respectively, with weighted-average exercise prices of $45.67 and $40.96 , respectively. There were 5.7 million options outstanding at December 28, 2019 with a weighted-average exercise price of $37.66 . The Company uses a binomial model to determine the fair value of its stock options. The weighted-average assumptions utilized to value these stock options are indicated in the following table: Three Months Ended December 28, December 29, Risk-free interest rate 1.7 % 3.0 % Expected volatility 33.6 % 34.3 % Expected life (in years) 4.8 4.8 Dividend yield — — Weighted average fair value of options granted $ 13.83 $ 13.41 The Company granted 0.7 million and 0.9 million restricted stock units (RSUs) during the three months ended December 28, 2019 and December 29, 2018 , respectively, with weighted-average grant date fair values of $45.64 and $40.98 per unit, respectively. In addition, the Company granted 0.1 million and 0.1 million performance stock units (PSUs) during the three months ended December 28, 2019 and December 29, 2018 , respectively, to members of its senior management team, which have a weighted-average grant date fair value of $45.65 and $40.97 per unit, respectively. Each recipient of PSUs is eligible to receive between zero and 200% of the target number of shares of the Company’s common stock at the end of three years provided the Company’s defined Return on Invested Capital metrics are achieved. The Company also granted 0.1 million of PSUs based on a one-year free cash flow measure (FCF) to its senior management team, which had a grant date fair value of $45.65 . Each recipient of FCF PSUs is eligible to receive between zero and 200% of the target number of shares of the Company's common stock at the end of the one year measurement period, but the FCF PSUs vest at the end of the three year service period. The Company is recognizing compensation expense for PSUs and FCF PSUs ratably over the required service period based on its estimate of the number of shares that will vest. If there is a change in the estimate of the number of shares that are probable of vesting, the Company cumulatively adjusts compensation expense in the period that the change in estimate is made. The Company also granted 0.1 million and 0.1 million market based awards (MSUs) to its senior management team during the nine months ended December 28, 2019 and December 29, 2018 , respectively. Each recipient of MSUs is eligible to receive between zero and 200% of the target number of shares of the Company’s common stock at the end of three years based upon achieving a certain total shareholder return relative to a defined peer group. The MSUs were valued at $43.78 and $55.13 per share using the Monte Carlo simulation model. The Company is recognizing compensation expense for the MSUs ratably over the service period. At December 28, 2019 , there was 2.6 million in aggregate RSUs, PSUs, FCF PSUs and MSUs outstanding. At December 28, 2019 , there was $30.4 million and $85.9 million of unrecognized compensation expense related to stock options and stock units (comprised of RSUs, PSUs, FCF PSUs and MSUs), respectively, to be recognized over a weighted-average period of 2.8 and 2.2 years, respectively.

Other Balance Sheet Information

Other Balance Sheet Information	3 Months Ended
	Dec. 28, 2019
Balance Sheet Related Disclosures [Abstract]
Other Balance Sheet Information	Other Balance Sheet Information December 28, September 28, Inventories Raw materials $ 154.5 $ 166.1 Work-in-process 54.0 54.5 Finished goods 172.3 224.3 $ 380.8 $ 444.9 Property, plant and equipment Equipment $ 385.2 $ 379.2 Equipment under customer usage agreements 448.2 435.5 Building and improvements 170.2 196.7 Leasehold improvements 43.6 61.7 Land 40.7 46.3 Furniture and fixtures 15.1 17.5 1,103.0 1,136.9 Less – accumulated depreciation and amortization (651.0 ) (666.0 ) $ 452.0 $ 470.9

Business Segments and Geographi

Business Segments and Geographic Information	3 Months Ended
	Dec. 28, 2019
Segment Reporting [Abstract]
Business Segments and Geographic Information	Business Segments and Geographic Information During the first fiscal quarter of 2020 and during fiscal 2019, the Company had five reportable segments: Diagnostics, Breast Health, GYN Surgical, Medical Aesthetics and Skeletal Health. The Company completed the sale of its Medical Aesthetics business on December 30, 2019 (the beginning of the second quarter of fiscal 2020). The Company measures and evaluates its reportable segments based on segment revenues and operating income adjusted to exclude the effect of non-cash charges, such as intangible asset amortization expense, intangible asset and goodwill impairment charges, acquisition related fair value adjustments and integration expenses, restructuring, divestiture and facility consolidation charges and other one-time or unusual items. Identifiable assets for the five principal operating segments consist of inventories, intangible assets, goodwill, and property, plant and equipment. The Company fully allocates depreciation expense to its five reportable segments. The Company has presented all other identifiable assets as corporate assets. There were no inter-segment revenues during the three months ended December 28, 2019 and December 29, 2018 . Segment information is as follows: Three Months Ended December 28, December 29, Total revenues: Diagnostics $ 311.5 $ 296.6 Breast Health 331.1 324.7 GYN Surgical 119.1 108.4 Medical Aesthetics 65.3 79.8 Skeletal Health 23.5 21.2 $ 850.5 $ 830.7 Income (loss) from operations: Diagnostics $ 49.5 $ 43.3 Breast Health 93.9 97.8 GYN Surgical 31.5 27.0 Medical Aesthetics (51.0 ) (25.2 ) Skeletal Health 0.9 (2.4 ) $ 124.8 $ 140.5 Depreciation and amortization: Diagnostics $ 59.1 $ 61.8 Breast Health 10.0 9.3 GYN Surgical 21.0 22.0 Medical Aesthetics 4.1 25.5 Skeletal Health 0.2 0.2 $ 94.4 $ 118.8 Capital expenditures: Diagnostics $ 18.1 $ 14.4 Breast Health 6.4 2.1 GYN Surgical 5.3 3.5 Medical Aesthetics 1.4 1.1 Skeletal Health 0.1 0.3 Corporate 0.2 1.2 $ 31.5 $ 22.6 December 28, September 28, Identifiable assets: Diagnostics $ 2,232.9 $ 2,276.6 Breast Health 1,199.3 1,127.8 GYN Surgical 1,303.4 1,328.6 Medical Aesthetics 132.7 159.3 Skeletal Health 31.7 27.3 Corporate 1,411.9 1,522.5 $ 6,311.9 $ 6,442.1 The Company had no customers that represented greater than 10% of consolidated revenues during the three months ended December 28, 2019 and December 29, 2018 . The Company operates in the major geographic areas noted in the below chart. Revenue data is based upon customer location. Other than the United States, no single country accounted for more than 10% of consolidated revenues. The Company’s sales in Europe are predominantly derived from France, Germany and the United Kingdom. The Company’s sales in Asia-Pacific are predominantly derived from China, Australia and Japan. The “Rest of World” designation includes Canada, Latin America and the Middle East. Revenues by geography as a percentage of total revenues were as follows: Three Months Ended December 28, December 29, United States 74.4 % 74.9 % Europe 12.9 % 12.2 % Asia-Pacific 8.3 % 8.4 % Rest of World 4.4 % 4.5 % 100.0 % 100.0 %

Income Taxes

Income Taxes	3 Months Ended
	Dec. 28, 2019
Income Tax Disclosure [Abstract]
Income Taxes	Income Taxes In accordance with ASC 740, Income Taxes (ASC 740), each interim period is considered integral to the annual period, and tax expense is measured using an estimated annual effective tax rate. An entity is required to record income tax expense each quarter based on its annual effective tax rate estimated for the full fiscal year and use that rate to provide for income taxes on a current year-to-date basis, adjusted for discrete taxable events that occur during the interim period. The Company’s effective tax rate for the three months ended December 28, 2019 was a benefit of 296.1% compared to a provision of 5.5% for the corresponding period in the prior year. The effective tax rate for the three months ended December 28, 2019 differed from the statutory tax rate primarily due to a $312.2 million discrete tax benefit related to the Medical Aesthetics business outside basis difference, partially offset by an increase in the Medical Aesthetics business valuation allowance. The outside basis difference is the difference between the carrying amount of an entity's investment for financial reporting purposes, and the underlying tax basis in that investment. An outside tax-over-book basis difference in an investment in a subsidiary results in the recognition of a deferred tax asset only when it becomes apparent that the reversal of the temporary difference will occur in the foreseeable future. As the Medical Aesthetics business met the assets held-for-sale criteria during the three months ended December 28, 2019, the requirement for recognition of the deferred tax asset for the outside basis difference was also met. For the three months ended December 29, 2018, the effective tax rate differed from the statutory tax rate primarily due to a $20.0 million discrete tax benefit recorded in the quarter related to an internal restructuring, earnings in jurisdictions subject to lower tax rates, and a $5.0 million benefit reduction from finalizing the computations under the Tax Cuts and Jobs Act enacted on December 22, 2017 (first quarter of fiscal 2018). Other Tax Accounting Pronouncements On October 24, 2016, the FASB issued ASU 2016-16, which removes the prohibition in ASC 740 against the immediate recognition of the current and deferred income tax effects of intra-entity transfers of assets other than inventory. Under ASU 2016-16, the selling (transferring) entity is required to recognize a current tax expense or benefit upon transfer of the asset. Similarly, the purchasing (receiving) entity is required to recognize a deferred tax asset or deferred tax liability, as well as the related deferred tax benefit or expense, upon receipt of the asset. This ASU is effective for annual periods beginning after December 15, 2017, and interim periods within those annual periods. The Company adopted ASU 2016-16 in the first quarter of fiscal 2019 on a modified retrospective basis through a cumulative-effect adjustment to decrease the opening balance of accumulated deficit within stockholders' equity as of September 30, 2018, the first day of fiscal 2019. This change in accounting principle resulted in an increase in deferred tax assets of $2.9 million , a decrease in accumulated deficit of $2.5 million , and a decrease in prepaid taxes of $0.4 million as of the beginning of the Company’s fiscal year beginning September 30, 2018. The Company was required to account for the internal restructuring discussed above under ASU 2016-16 and recorded a $29.1 million increase to income tax expense and income tax liabilities and a decrease of $49.1 million to deferred tax expense and net deferred tax liabilities for the three months ended December 29, 2018. The net result was an increase to net income of $20.0 million , or an earnings per share increase of $0.07 . Non-Income Tax Matters The Company is subject to tax examinations for value added, sales-based, payroll, and other non-income tax items. A number of these examinations are ongoing in various jurisdictions. The Company takes certain non-income tax positions in the jurisdictions in which it operates pursuant to ASC 450. In the normal course of business, the Company's positions and conclusions related to its non-income tax positions could be challenged, resulting in assessments by governmental authorities. While the Company believes estimated losses previously recorded are reasonable, certain audits are still ongoing and additional charges could be recorded in the future.

Intangible Assets and Goodwill

Intangible Assets and Goodwill	3 Months Ended
	Dec. 28, 2019
Goodwill and Intangible Assets Disclosure [Abstract]
Intangible Assets and Goodwill	Intangible Assets and Goodwill Intangible assets consisted of the following: Description As of December 28, 2019 As of September 28, 2019 Gross Carrying Value Accumulated Amortization Gross Carrying Value Accumulated Amortization Acquired intangible assets: Developed technology $ 3,909.3 $ 2,716.7 $ 3,927.7 $ 2,654.8 Customer relationships 527.7 454.5 525.5 447.5 Trade names 244.7 173.6 245.4 171.1 Distribution agreement — — 2.5 — Non-competition agreements 1.5 1.0 1.4 0.9 Business licenses 2.3 2.2 2.3 2.2 Total acquired intangible assets $ 4,685.5 $ 3,348.0 $ 4,704.8 $ 3,276.5 Internal-use software 50.8 40.9 53.9 43.4 Capitalized software embedded in products 27.7 8.1 27.9 6.9 Total intangible assets $ 4,764.0 $ 3,397.0 $ 4,786.6 $ 3,326.8 In the first quarter of fiscal 2020, the Company's Medical Aesthetics business met the criteria to be designated as assets held-for-sale. As a result, the Company recorded a $30.2 million charge to record the asset group at fair value less costs to sell. In addition, developed technology, customer lists, tradenames, and distribution agreement related to Medical Aesthetics of $24.1 million , $0.9 million , $2.0 million , and $1.2 million , respectively, were reclassified accordingly in the Company's Consolidated Balance Sheet to assets held-for-sale as of December 28, 2019. The estimated remaining amortization expense of the Company's acquired intangible assets as of December 28, 2019 for each of the five succeeding fiscal years is as follows: Remainder of Fiscal 2020 $ 213.7 Fiscal 2021 $ 263.6 Fiscal 2022 $ 253.2 Fiscal 2023 $ 155.8 Fiscal 2024 $ 144.8

Product Warranties

Product Warranties	3 Months Ended
	Dec. 28, 2019
Guarantees [Abstract]
Product Warranties	Product Warranties Product warranty activity was as follows: Balance at Beginning of Period Provisions Acquired Settlements/ Adjustments Balance at End of Period Three Months Ended: December 28, 2019 $ 13.9 $ 3.8 $ 0.5 $ (4.1 ) $ 14.1 December 29, 2018 $ 15.9 $ 2.6 $ — $ (3.4 ) $ 15.1

Accumulated Other Comprehensive

Accumulated Other Comprehensive Loss	3 Months Ended
	Dec. 28, 2019
Accumulated Other Comprehensive Income [Abstract]
Accumulated Other Comprehensive Loss	Accumulated Other Comprehensive Loss The following tables summarize the changes in accumulated balances of other comprehensive loss for the periods presented: Three Months Ended December 28, 2019 Foreign Currency Translation Pension Plans Hedged Interest Rate Caps Hedged Interest Rate Swaps Total Beginning Balance $ (41.4 ) $ (1.7 ) $ (2.7 ) $ 3.5 $ (42.3 ) Other comprehensive income (loss) before reclassifications 8.3 — — 4.0 12.3 Amounts reclassified to statement of income — — 1.3 — 1.3 Ending Balance $ (33.1 ) $ (1.7 ) $ (1.4 ) $ 7.5 $ (28.7 ) Three Months Ended December 29, 2018 Foreign Currency Translation Pension Plans Hedged Interest Rate Caps Total Beginning Balance $ (26.6 ) $ (1.1 ) $ 2.2 $ (25.5 ) Other comprehensive income (loss) before reclassifications (3.2 ) — (3.9 ) (7.1 ) Amounts reclassified to statement of income — — 0.7 0.7 Ending Balance $ (29.8 ) $ (1.1 ) $ (1.0 ) $ (31.9 )

Share Repurchase

Share Repurchase	3 Months Ended
	Dec. 28, 2019
Equity [Abstract]
Share Repurchase	Share Repurchase On June 13, 2018, the Board of Directors authorized a share repurchase plan to repurchase up to $500.0 million of the Company's outstanding common stock. This share repurchase plan was effective August 1, 2018 and expires on March 27, 2020. Under this authorization, during the first quarter of fiscal 2020, the Company repurchased 1.5 million shares of its common stock for a total consideration of $80.9 million . As of December 28, 2019, $130.6 million remained under this authorization. Subsequent to December 28, 2019, the Company repurchased 0.9 million shares of its common stock for a total consideration of $50.0 million . On November 19, 2019, the Board of Directors authorized the Company to repurchase up to $205 million of its outstanding shares pursuant to an accelerated share repurchase ("ASR") agreement. On November 22, 2019, the Company executed the ASR agreement with Goldman Sachs & Co. ("Goldman Sachs") pursuant to which the Company will repurchase $205 million of the Company's common stock. The initial delivery, of approximately 80% of the shares under the ASR, was 3.3 million shares for which the Company has initially allocated $164.0 million of the $205 million paid to Goldman Sachs. The number of shares of Hologic's common stock that Hologic may receive, or may be required to remit, upon final settlement under the agreement will be based upon the average daily volume weighted-average price of Hologic's common stock during the term of the program, less a negotiated discount. Final settlement of the transaction under the ASR is expected to occur in the second quarter of fiscal 2020. If Hologic is obligated to make an adjustment payment to Goldman Sachs under the ASR, Hologic is able to satisfy such obligation in shares of Hologic's common stock or cash. The Company evaluated the nature of the forward contract aspect of the ASR under ASC 815 and concluded equity classification was appropriate. On November 19, 2019, the Board of Directors also authorized a new share repurchase plan to repurchase up to $500.0 million

New Accounting Pronouncements

New Accounting Pronouncements	3 Months Ended
	Dec. 28, 2019
Accounting Policies [Abstract]
New Accounting Pronouncements	New Accounting Pronouncements See Note 1 for Recently Adopted Accounting Pronouncements. In June 2016, the FASB issued ASU No. 2016-13, Financial Instruments - Credit Losses (Topic 326) and subsequently a number of improvements. The guidance requires that financial assets measured at amortized cost be presented at the net amount expected to be collected. The allowance for credit losses is a valuation account that is deducted from the amortized cost basis. The income statement reflects the measurement of credit losses for newly recognized financial assets, as well as the expected credit losses during the period. The measurement of expected credit losses is based upon historical experience, current conditions, and reasonable and supportable forecasts that affect the collectability of the reported amount. Credit losses relating to available-for-sale debt securities will be recorded through an allowance for credit losses rather than as a direct write-down to the security. The updated guidance is effective for annual periods beginning after December 15, 2019, and is applicable to the Company in fiscal 2021. Early adoption is permitted. The Company is currently evaluating the impact of the adoption of ASU 2016-13, as well as all codification improvements in ASU 2019-04, ASU 2019-10 and ASU 2019-11, on its consolidated financial position and results of operations. In November 2019, the FASB issued ASU No. 2019-08, Compensation - Stock Compensation (Topic 718) and Revenue from Contracts with Customers (Topic 606) . The guidance identifies, evaluates, and improves areas of GAAP for which cost and complexity can be reduced while maintaining or improving the usefulness of the information provided. The amendments in that Update expanded the scope of Topic 718 to include share-based payment transactions for acquiring goods and services from nonemployees. For entities that have adopted the amendments in Update 2018-07, the updated guidance is effective for annual periods beginning after December 15, 2019, and is applicable to the Company in fiscal 2021. Early adoption is permitted. The Company is currently evaluating the impact of the adoption of ASU 2019-08 on its consolidated financial position and results of operations. In December 2019, the FASB issued ASU No. 2019-12, Income Taxes (Topic 740) Simplifying the Accounting for Income Taxes. The Board is issuing this Update as part of its initiative to reduce complexity in accounting standards (the Simplification Initiative). The objective of the Simplification Initiative is to identify, evaluate, and improve areas of GAAP for which cost and complexity can be reduced while maintaining or improving the usefulness of the information provided to users of financial statements. The specific areas of potential simplification in this Update were submitted by stakeholders as part of the Simplification Initiative. For public business entities, the amendments in this Update are effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2020. The Company is currently evaluating the impact of the adoption of ASU 2019-12 on its consolidated financial position and results of operations.

New Accounting Pronouncements (

New Accounting Pronouncements (Policies)	3 Months Ended
	Dec. 28, 2019
Accounting Policies [Abstract]
New Accounting Pronouncements	New Accounting Pronouncements See Note 1 for Recently Adopted Accounting Pronouncements. In June 2016, the FASB issued ASU No. 2016-13, Financial Instruments - Credit Losses (Topic 326) and subsequently a number of improvements. The guidance requires that financial assets measured at amortized cost be presented at the net amount expected to be collected. The allowance for credit losses is a valuation account that is deducted from the amortized cost basis. The income statement reflects the measurement of credit losses for newly recognized financial assets, as well as the expected credit losses during the period. The measurement of expected credit losses is based upon historical experience, current conditions, and reasonable and supportable forecasts that affect the collectability of the reported amount. Credit losses relating to available-for-sale debt securities will be recorded through an allowance for credit losses rather than as a direct write-down to the security. The updated guidance is effective for annual periods beginning after December 15, 2019, and is applicable to the Company in fiscal 2021. Early adoption is permitted. The Company is currently evaluating the impact of the adoption of ASU 2016-13, as well as all codification improvements in ASU 2019-04, ASU 2019-10 and ASU 2019-11, on its consolidated financial position and results of operations.

Revenue (Tables)

Revenue (Tables)	3 Months Ended
	Dec. 28, 2019
Revenue from Contract with Customer [Abstract]
Disaggregation of Revenue	The following table provides revenue from contracts with customers by business and geographic region on a disaggregated basis: Three Months Ended December 28, 2019 Business ( in millions ) United States International Total Diagnostics: Cytology & Perinatal $ 77.5 $ 43.5 $ 121.0 Molecular Diagnostics 142.1 36.4 178.5 Blood Screening 12.0 — 12.0 Total $ 231.6 $ 79.9 $ 311.5 Breast Health: Breast Imaging $ 209.4 $ 65.4 $ 274.8 Interventional Breast Solutions 47.1 9.2 56.3 Total $ 256.5 $ 74.6 $ 331.1 GYN Surgical $ 98.8 $ 20.3 $ 119.1 Medical Aesthetics $ 30.9 $ 34.4 $ 65.3 Skeletal Health $ 14.9 $ 8.6 $ 23.5 $ 632.7 $ 217.8 $ 850.5 Three Months Ended December 29, 2018 Business (in millions) United States International Total Diagnostics: Cytology & Perinatal $ 79.2 $ 38.9 $ 118.1 Molecular Diagnostics 134.1 30.2 164.3 Blood Screening 14.2 — 14.2 Total $ 227.5 $ 69.1 $ 296.6 Breast Health: Breast Imaging $ 206.5 $ 63.2 $ 269.7 Interventional Breast Solutions 46.1 8.9 55.0 Total $ 252.6 $ 72.1 $ 324.7 GYN Surgical $ 91.1 $ 17.3 $ 108.4 Medical Aesthetics $ 37.3 $ 42.5 $ 79.8 Skeletal Health $ 13.3 $ 7.9 $ 21.2 $ 621.8 $ 208.9 $ 830.7 Three Months Ended Geographic Regions ( in millions ) December 28, 2019 December 29, 2018 United States $ 632.7 $ 621.8 Europe 109.4 101.1 Asia-Pacific 70.2 69.6 Rest of World 38.2 38.2 $ 850.5 $ 830.7 The following table provides revenue recognized by source: Three Months Ended Revenue by type (in millions) December 28, 2019 December 29, 2018 Capital equipment, components and software $ 232.9 $ 248.3 Consumables 466.4 434.8 Service 145.0 141.8 Other 6.2 5.8 $ 850.5 $ 830.7

Leases (Tables)

Leases (Tables)	3 Months Ended
	Dec. 28, 2019
Leases [Abstract]
Schedule of Lessee Lease Assets And Liabilities	The following table presents the weighted average remaining lease term and discount rate information related to the Company's operating and finance leases: December 28, 2019 Operating Leases Finance Lease Weighted average remaining lease term 6.09 8.39 Weighted average discount rate 1.93 % 5.1 % The following table presents supplemental balance sheet information related to the Company's operating and finance leases: December 28, 2019 Balance Sheet Location Operating Leases Finance Lease Assets Lease right-of-use assets Other assets $ 89.6 $ — Lease right-of-use assets Property, plant and equipment $ — 9.9 Liabilities Operating lease liabilities (current) Accrued expenses $ 22.2 $ — Finance lease liabilities (current) Finance lease obligations - short term $ — $ 1.8 Operating lease liabilities (non-current) Other long-term liabilities $ 72.3 $ — Finance lease liabilities (non-current) Finance lease obligations - long term $ — $ 18.8
Schedule of Additional Lease Information	The following table provides information related to the Company’s operating and finance leases: Three Months Ended December 28, 2019 Operating lease cost (a) $ 7.0 Finance lease cost - amortization of right-of-use assets $ 0.3 Finance lease cost - interest cost $ 0.3 Cash paid for amounts included in the measurement of lease liabilities: Operating cash flows from finance leases $ 0.3 Operating cash flows from operating leases 5.9 Financing cash flows from finance leases $ 0.4 Total cash paid for amounts included in the measurement of lease liabilities $ 6.6 ROU assets arising from entering into new operating lease obligations $ 1.4 (a) Includes short-term lease expense and variable lease costs, which were immaterial in the three months ended December 28, 2019.
Schedule of Operating Lease Liability Maturities	The following table presents the future minimum lease payments under non-cancellable operating lease liabilities and finance lease as of December 28, 2019 : Fiscal Year Operating Leases Finance Lease 2020 remaining $ 17.8 $ 2.1 2021 22.2 2.8 2022 17.3 3.0 2023 10.7 3.0 2024 8.7 3.0 Thereafter 24.0 11.5 Total future minimum lease payments 100.7 25.4 Less: imputed interest (6.2 ) (4.8 ) Present value of lease liabilities $ 94.5 $ 20.6
Schedule of Finance Lease Liability Maturities	The following table presents the future minimum lease payments under non-cancellable operating lease liabilities and finance lease as of December 28, 2019 : Fiscal Year Operating Leases Finance Lease 2020 remaining $ 17.8 $ 2.1 2021 22.2 2.8 2022 17.3 3.0 2023 10.7 3.0 2024 8.7 3.0 Thereafter 24.0 11.5 Total future minimum lease payments 100.7 25.4 Less: imputed interest (6.2 ) (4.8 ) Present value of lease liabilities $ 94.5 $ 20.6

Fair Value Measurements (Tables

Fair Value Measurements (Tables)	3 Months Ended
	Dec. 28, 2019
Fair Value Disclosures [Abstract]
Fair Value Assets and Liabilities Measured on Recurring Basis	Assets and liabilities measured and recorded at fair value on a recurring basis consisted of the following at December 28, 2019 : Fair Value at Reporting Date Using Balance as of December 28, 2019 Quoted Prices in Active Market for Identical Assets (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) Assets: Interest rate swaps - derivative $ 10.4 $ — $ 10.4 $ — Foreign currency option contracts 0.3 — 0.3 — Forward foreign currency contracts 0.5 — 0.5 — Total $ 11.2 $ — $ 11.2 $ — Liabilities: Contingent consideration $ 9.3 $ — $ — $ 9.3 Forward foreign currency contracts 1.2 — 1.2 — Total $ 10.5 $ — $ 1.2 $ 9.3

Business Combinations (Tables)

Business Combinations (Tables)	3 Months Ended
	Dec. 28, 2019
Faxitron
Business Acquisition [Line Items]
Schedule of Recognized Identified Assets Acquired and Liabilities Assumed	The total purchase price was allocated to SSI's preliminary tangible and identifiable intangible assets and liabilities based on the estimated fair values of those assets as of November 21, 2019, as set forth below. The preliminary purchase price allocation is as follows: Cash $ 2.6 Accounts receivable 7.1 Inventory 10.0 Property, plant and equipment 6.5 Other assets 4.4 Accounts payable and accrued expenses (13.0 ) Deferred revenue (1.8 ) Short and long-term debt (8.8 ) Other liabilities (3.8 ) Identifiable intangible assets: — Developed technology 33.2 Customer relationships 3.1 Trade names 3.5 Deferred income taxes, net (2.4 ) Goodwill 28.7 Purchase Price $ 69.3
Focal Therapeutics
Business Acquisition [Line Items]
Schedule of Recognized Identified Assets Acquired and Liabilities Assumed	The total purchase price was allocated to Focal's tangible and identifiable intangible assets and liabilities based on the estimated fair values of those assets as of October 1, 2018, as set forth below: Cash $ 2.2 Accounts receivable 2.0 Inventory 7.9 Other assets 0.5 Accounts payable and accrued expenses (5.6 ) Long-term debt (2.5 ) Identifiable intangible assets: Developed technology 83.1 In-process research and development 11.4 Trade names 2.7 Deferred income taxes, net (12.7 ) Goodwill 31.1 Purchase Price $ 120.1

Disposition Disposition (Tables

Disposition Disposition (Tables)	3 Months Ended
	Dec. 28, 2019
Discontinued Operations and Disposal Groups [Abstract]
Disclosure of Long Lived Assets Held-for-sale	Assets held-for sale comprise the following as of December 28, 2019: Assets: December 28, 2019 Cash $ 10.7 Accounts Receivable 59.6 Inventory 90.6 Prepaid expenses and other current assets 7.7 Property, plant, and equipment 4.0 Intangible assets 28.2 Other assets 9.8 Total assets held-for-sale $ 210.6 Liabilities: Accounts payable $ 12.3 Accrued expenses 49.0 Deferred revenue 16.6 Total liabilities held-for-sale $ 77.9

Borrowings and Credit Arrange_2

Borrowings and Credit Arrangements (Tables)	3 Months Ended
	Dec. 28, 2019
Debt Disclosure [Abstract]
Company's Borrowings	The Company’s borrowings consisted of the following: December 28, September 28, Current debt obligations, net of debt discount and deferred issuance costs: Term Loan $ 46.8 $ 37.4 Securitization Program 250.0 234.0 Debt assumed from SSI acquisition 5.4 — Total current debt obligations $ 302.2 $ 271.4 Long-term debt obligations, net of debt discount and deferred issuance costs: Term Loan 1,434.3 1,452.4 Debt assumed from SSI acquisition 3.2 — 2025 Senior Notes 937.8 937.3 2028 Senior Notes 394.1 393.9 Total long-term debt obligations $ 2,769.4 $ 2,783.6 Total debt obligations $ 3,071.6 $ 3,055.0
Schedule of Line of Credit Facilities
Schedule Of Interest Expense Under Convertible Notes	8. Interest expense for the 2028 Senior Notes and 2025 Senior Notes is as follows: Three Months Ended December 28, 2019 December 29, 2018 Interest Rate Interest Expense Interest Expense 2028 Senior Notes 4.625 % $ 4.8 $ 4.8 2025 Senior Notes 4.375 % 10.9 10.9 Total $ 15.7 $ 15.7

Derivatives (Tables)

Derivatives (Tables)	3 Months Ended
	Dec. 28, 2019
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Schedule of Derivative Assets at Fair Value	The table below presents the fair value of the Company's derivative financial instruments as well as their classification on the balance sheet as of December 28, 2019 : Balance Sheet Location December 28, 2019 September 28, 2019 Assets: Derivative instruments designated as a cash flow hedge: Interest rate cap agreements Prepaid expenses and other current assets $ — $ 0.1 Interest rate swap contract Other assets 10.4 4.7 $ 10.4 $ 4.8 Derivatives not designated as hedging instruments: Forward foreign currency contracts Prepaid expenses and other current assets $ 0.5 $ 0.9 Foreign currency option contracts Prepaid expenses and other current assets 0.3 2.0 $ 0.8 $ 2.9 Liabilities: Derivatives not designated as hedging instruments: Forward foreign currency contracts Accrued expenses $ 1.2 $ 0.1
Schedule of Unrealized Loss Recognized in AOCI	The following table presents the unrealized gain (loss) recognized in AOCI related to the interest rate caps and interest rate swap for the following reporting periods: Three Months Ended December 28, 2019 December 29, 2018 Amount of gain (loss) recognized in other comprehensive income, net of taxes: Interest rate swap $ 4.3 $ — Interest rate cap agreements (0.3 ) (3.9 ) Total $ 4.0 $ (3.9 )
Schedule of Adjustment to Fair Value within the Consolidated Statements of Income	The following table presents the adjustment to fair value (realized and unrealized) recorded within the Consolidated Statements of Income for derivative instruments for which the Company did not elect hedge accounting: Derivatives not classified as hedging instruments Amount of (Loss) Gain Recognized in Income Three Months Ended December 28, 2019 Three Months Ended December 29, 2018 Forward foreign currency contracts $ (1.5 ) $ 5.1 Foreign currency option contracts (1.7 ) — Total $ (3.2 ) $ 5.1

Net Income (Loss) Per Share (Ta

Net Income (Loss) Per Share (Tables)	3 Months Ended
	Dec. 28, 2019
Earnings Per Share [Abstract]
Reconciliation of Basic and Diluted Share Amounts	A reconciliation of basic and diluted share amounts is as follows: Three Months Ended December 28, December 29, Basic weighted average common shares outstanding 267,893 270,590 Weighted average common stock equivalents from assumed exercise of stock options and issuance of stock units 1,828 1,782 Diluted weighted average common shares outstanding 269,721 272,372 Weighted-average anti-dilutive shares related to: Outstanding stock options 1,290 3,339 Stock Units 1 4

Stock-Based Compensation (Table

Stock-Based Compensation (Tables)	3 Months Ended
	Dec. 28, 2019
Share-based Payment Arrangement [Abstract]
Stock-Based Compensation Expense in Consolidated Statements of Operations	The following presents stock-based compensation expense in the Company’s Consolidated Statements of Operations: Three Months Ended December 28, December 29, Cost of revenues $ 2.0 $ 2.0 Research and development 2.4 2.7 Selling and marketing 2.8 2.7 General and administrative 10.9 9.7 $ 18.1 $ 17.1
Weighted-Average Assumptions Utilized to Value Stock Options	The Company uses a binomial model to determine the fair value of its stock options. The weighted-average assumptions utilized to value these stock options are indicated in the following table: Three Months Ended December 28, December 29, Risk-free interest rate 1.7 % 3.0 % Expected volatility 33.6 % 34.3 % Expected life (in years) 4.8 4.8 Dividend yield — — Weighted average fair value of options granted $ 13.83 $ 13.41

Other Balance Sheet Informati_2

Other Balance Sheet Information (Tables)	3 Months Ended
	Dec. 28, 2019
Balance Sheet Related Disclosures [Abstract]
Other Balance Sheet Information of Inventories	December 28, September 28, Inventories Raw materials $ 154.5 $ 166.1 Work-in-process 54.0 54.5 Finished goods 172.3 224.3 $ 380.8 $ 444.9
Other Balance Sheet Information of Property, Plant and Equipment	Property, plant and equipment Equipment $ 385.2 $ 379.2 Equipment under customer usage agreements 448.2 435.5 Building and improvements 170.2 196.7 Leasehold improvements 43.6 61.7 Land 40.7 46.3 Furniture and fixtures 15.1 17.5 1,103.0 1,136.9 Less – accumulated depreciation and amortization (651.0 ) (666.0 ) $ 452.0 $ 470.9

Business Segments and Geograp_2

Business Segments and Geographic Information (Tables)	3 Months Ended
	Dec. 28, 2019
Segment Reporting [Abstract]
Segment Information	Segment information is as follows: Three Months Ended December 28, December 29, Total revenues: Diagnostics $ 311.5 $ 296.6 Breast Health 331.1 324.7 GYN Surgical 119.1 108.4 Medical Aesthetics 65.3 79.8 Skeletal Health 23.5 21.2 $ 850.5 $ 830.7 Income (loss) from operations: Diagnostics $ 49.5 $ 43.3 Breast Health 93.9 97.8 GYN Surgical 31.5 27.0 Medical Aesthetics (51.0 ) (25.2 ) Skeletal Health 0.9 (2.4 ) $ 124.8 $ 140.5 Depreciation and amortization: Diagnostics $ 59.1 $ 61.8 Breast Health 10.0 9.3 GYN Surgical 21.0 22.0 Medical Aesthetics 4.1 25.5 Skeletal Health 0.2 0.2 $ 94.4 $ 118.8 Capital expenditures: Diagnostics $ 18.1 $ 14.4 Breast Health 6.4 2.1 GYN Surgical 5.3 3.5 Medical Aesthetics 1.4 1.1 Skeletal Health 0.1 0.3 Corporate 0.2 1.2 $ 31.5 $ 22.6 December 28, September 28, Identifiable assets: Diagnostics $ 2,232.9 $ 2,276.6 Breast Health 1,199.3 1,127.8 GYN Surgical 1,303.4 1,328.6 Medical Aesthetics 132.7 159.3 Skeletal Health 31.7 27.3 Corporate 1,411.9 1,522.5 $ 6,311.9 $ 6,442.1
Revenues by Geography	Revenues by geography as a percentage of total revenues were as follows: Three Months Ended December 28, December 29, United States 74.4 % 74.9 % Europe 12.9 % 12.2 % Asia-Pacific 8.3 % 8.4 % Rest of World 4.4 % 4.5 % 100.0 % 100.0 %

Intangible Assets and Goodwill

Intangible Assets and Goodwill (Tables)	3 Months Ended
	Dec. 28, 2019
Goodwill and Intangible Assets Disclosure [Abstract]
Schedule of Intangible Assets	Intangible assets consisted of the following: Description As of December 28, 2019 As of September 28, 2019 Gross Carrying Value Accumulated Amortization Gross Carrying Value Accumulated Amortization Acquired intangible assets: Developed technology $ 3,909.3 $ 2,716.7 $ 3,927.7 $ 2,654.8 Customer relationships 527.7 454.5 525.5 447.5 Trade names 244.7 173.6 245.4 171.1 Distribution agreement — — 2.5 — Non-competition agreements 1.5 1.0 1.4 0.9 Business licenses 2.3 2.2 2.3 2.2 Total acquired intangible assets $ 4,685.5 $ 3,348.0 $ 4,704.8 $ 3,276.5 Internal-use software 50.8 40.9 53.9 43.4 Capitalized software embedded in products 27.7 8.1 27.9 6.9 Total intangible assets $ 4,764.0 $ 3,397.0 $ 4,786.6 $ 3,326.8
Schedule of Estimated Amortization Expense	The estimated remaining amortization expense of the Company's acquired intangible assets as of December 28, 2019 for each of the five succeeding fiscal years is as follows: Remainder of Fiscal 2020 $ 213.7 Fiscal 2021 $ 263.6 Fiscal 2022 $ 253.2 Fiscal 2023 $ 155.8 Fiscal 2024 $ 144.8

Product Warranties (Tables)

Product Warranties (Tables)	3 Months Ended
	Dec. 28, 2019
Guarantees [Abstract]
Product Warranty Activity	Product warranty activity was as follows: Balance at Beginning of Period Provisions Acquired Settlements/ Adjustments Balance at End of Period Three Months Ended: December 28, 2019 $ 13.9 $ 3.8 $ 0.5 $ (4.1 ) $ 14.1 December 29, 2018 $ 15.9 $ 2.6 $ — $ (3.4 ) $ 15.1

Accumulated Other Comprehensi_2

Accumulated Other Comprehensive Loss (Tables)	3 Months Ended
	Dec. 28, 2019
Accumulated Other Comprehensive Income [Abstract]
Changes in Accumulated Other Comprehensive Income	The following tables summarize the changes in accumulated balances of other comprehensive loss for the periods presented: Three Months Ended December 28, 2019 Foreign Currency Translation Pension Plans Hedged Interest Rate Caps Hedged Interest Rate Swaps Total Beginning Balance $ (41.4 ) $ (1.7 ) $ (2.7 ) $ 3.5 $ (42.3 ) Other comprehensive income (loss) before reclassifications 8.3 — — 4.0 12.3 Amounts reclassified to statement of income — — 1.3 — 1.3 Ending Balance $ (33.1 ) $ (1.7 ) $ (1.4 ) $ 7.5 $ (28.7 ) Three Months Ended December 29, 2018 Foreign Currency Translation Pension Plans Hedged Interest Rate Caps Total Beginning Balance $ (26.6 ) $ (1.1 ) $ 2.2 $ (25.5 ) Other comprehensive income (loss) before reclassifications (3.2 ) — (3.9 ) (7.1 ) Amounts reclassified to statement of income — — 0.7 0.7 Ending Balance $ (29.8 ) $ (1.1 ) $ (1.0 ) $ (31.9 )

Basis of Presentation Details (

Basis of Presentation Details (Details) $ in Millions	Dec. 28, 2019USD ($)
Basis of Presentation [Abstract]
Right of use asset recognized - operating	$ 91.7
Right of use asset recognized - Finance Lease	10.2
Right of use liability recognized - Operating lease	96.6
Right of use liability recognized - Finance lease	21
Derecognition of property, plant and equipment	32.6
Derecognition of finance leases	$ 35.2

Revenue - Remaining Performance

Revenue - Remaining Performance Obligation (Details)	Dec. 28, 2019
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2019-01-01
Disaggregation of Revenue [Line Items]
Revenue, Remaining Performance Obligation, Percentage	30.00%
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2020-01-01
Disaggregation of Revenue [Line Items]
Revenue, Remaining Performance Obligation, Percentage	29.00%
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Period	1 year
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2021-01-01
Disaggregation of Revenue [Line Items]
Revenue, Remaining Performance Obligation, Percentage	23.00%
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Period	1 year
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2022-01-01
Disaggregation of Revenue [Line Items]
Revenue, Remaining Performance Obligation, Percentage	12.00%
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Period	1 year
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2023-01-01
Disaggregation of Revenue [Line Items]
Revenue, Remaining Performance Obligation, Percentage	6.00%
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Period	1 year

Revenue - Business Revenue (Det

Revenue - Business Revenue (Details) - USD ($) $ in Millions	3 Months Ended
	Dec. 28, 2019	Dec. 29, 2018
Disaggregation of Revenue [Line Items]
Revenues	$ 850.5	$ 830.7
United States
Disaggregation of Revenue [Line Items]
Revenues	632.7	621.8
International
Disaggregation of Revenue [Line Items]
Revenues	217.8	208.9
Diagnostics
Disaggregation of Revenue [Line Items]
Revenues	311.5	296.6
Diagnostics | United States
Disaggregation of Revenue [Line Items]
Revenues	231.6	227.5
Diagnostics | International
Disaggregation of Revenue [Line Items]
Revenues	79.9	69.1
Diagnostics | Cytology & Perinatal
Disaggregation of Revenue [Line Items]
Revenues	121	118.1
Diagnostics | Cytology & Perinatal | United States
Disaggregation of Revenue [Line Items]
Revenues	77.5	79.2
Diagnostics | Cytology & Perinatal | International
Disaggregation of Revenue [Line Items]
Revenues	43.5	38.9
Diagnostics | Molecular Diagnostics
Disaggregation of Revenue [Line Items]
Revenues	178.5	164.3
Diagnostics | Molecular Diagnostics | United States
Disaggregation of Revenue [Line Items]
Revenues	142.1	134.1
Diagnostics | Molecular Diagnostics | International
Disaggregation of Revenue [Line Items]
Revenues	36.4	30.2
Diagnostics | Blood Screening
Disaggregation of Revenue [Line Items]
Revenues	12	14.2
Diagnostics | Blood Screening | United States
Disaggregation of Revenue [Line Items]
Revenues	12	14.2
Diagnostics | Blood Screening | International
Disaggregation of Revenue [Line Items]
Revenues	0	0
Breast Health
Disaggregation of Revenue [Line Items]
Revenues	331.1	324.7
Breast Health | United States
Disaggregation of Revenue [Line Items]
Revenues	256.5	252.6
Breast Health | International
Disaggregation of Revenue [Line Items]
Revenues	74.6	72.1
Breast Health | Breast Imaging
Disaggregation of Revenue [Line Items]
Revenues	274.8	269.7
Breast Health | Breast Imaging | United States
Disaggregation of Revenue [Line Items]
Revenues	209.4	206.5
Breast Health | Breast Imaging | International
Disaggregation of Revenue [Line Items]
Revenues	65.4	63.2
Breast Health | Interventional Breast Solutions
Disaggregation of Revenue [Line Items]
Revenues	56.3	55
Breast Health | Interventional Breast Solutions | United States
Disaggregation of Revenue [Line Items]
Revenues	47.1	46.1
Breast Health | Interventional Breast Solutions | International
Disaggregation of Revenue [Line Items]
Revenues	9.2	8.9
GYN Surgical
Disaggregation of Revenue [Line Items]
Revenues	119.1	108.4
GYN Surgical | United States
Disaggregation of Revenue [Line Items]
Revenues	98.8	91.1
GYN Surgical | International
Disaggregation of Revenue [Line Items]
Revenues	20.3	17.3
Medical Aesthetics
Disaggregation of Revenue [Line Items]
Revenues	65.3	79.8
Medical Aesthetics | United States
Disaggregation of Revenue [Line Items]
Revenues	30.9	37.3
Medical Aesthetics | International
Disaggregation of Revenue [Line Items]
Revenues	34.4	42.5
Skeletal Health
Disaggregation of Revenue [Line Items]
Revenues	23.5	21.2
Skeletal Health | United States
Disaggregation of Revenue [Line Items]
Revenues	14.9	13.3
Skeletal Health | International
Disaggregation of Revenue [Line Items]
Revenues	$ 8.6	$ 7.9

Revenue - Geographical Revenue

Revenue - Geographical Revenue (Details) - USD ($) $ in Millions	3 Months Ended
	Dec. 28, 2019	Dec. 29, 2018
Disaggregation of Revenue [Line Items]
Revenues	$ 850.5	$ 830.7
United States
Disaggregation of Revenue [Line Items]
Revenues	632.7	621.8
Europe
Disaggregation of Revenue [Line Items]
Revenues	109.4	101.1
Asia-Pacific
Disaggregation of Revenue [Line Items]
Revenues	70.2	69.6
Rest of World
Disaggregation of Revenue [Line Items]
Revenues	$ 38.2	$ 38.2

Revenue - Revenue by Type (Deta

Revenue - Revenue by Type (Details) - USD ($) $ in Millions	3 Months Ended
	Dec. 28, 2019	Dec. 29, 2018
Disaggregation of Revenue [Line Items]
Revenues	$ 850.5	$ 830.7
Capital equipment, components and software
Disaggregation of Revenue [Line Items]
Revenues	232.9	248.3
Consumables
Disaggregation of Revenue [Line Items]
Revenues	466.4	434.8
Service
Disaggregation of Revenue [Line Items]
Revenues	145	141.8
Other
Disaggregation of Revenue [Line Items]
Revenues	$ 6.2	$ 5.8

Revenue - Narrative (Details)

Revenue - Narrative (Details) $ in Millions	3 Months Ended
	Dec. 28, 2019USD ($)
Revenue from Contract with Customer [Abstract]
Revenue, Remaining Performance Obligation, Amount	$ 500.7
Contract with Customer, Liability, Change in Timeframe, Performance Obligation Satisfied, Revenue Recognized	$ 51.3

Leases (Details)

Leases (Details) $ in Millions	3 Months Ended
	Dec. 28, 2019	Sep. 28, 2019USD ($)
Lessee, Lease, Description [Line Items]
Period with option to terminate lease	1 year
Extension period	20 years
Weighted average discount rate (percentage)	0.0257
Finance lease liability, current		$ 1.8
Finance lease liabilities (non-current)		$ 19.2
Lease revenue as a percentage of total (percentage)	0.03
Minimum
Lessee, Lease, Description [Line Items]
Lessee, Operating And Finance Lease, Remaining Lease Term	1 year
Maximum
Lessee, Lease, Description [Line Items]
Lessee, Operating And Finance Lease, Remaining Lease Term	15 years

Leases - Supplemental Balance S

Leases - Supplemental Balance Sheet Information (Details) - USD ($)	Dec. 28, 2019	Sep. 28, 2019
Lessee, Lease, Description [Line Items]
Finance lease liabilities (current)		$ 1,800,000
Finance lease liabilities (non-current)		$ 19,200,000
Operating Lease, Weighted Average Remaining Lease Term	6 years 1 month 2 days
Finance Lease, Weighted Average Remaining Lease Term	8 years 4 months 20 days
Operating Leases, Weighted average discount rate	1.93%
Financing Leases, Weighted average discount rate	5.10%
Other assets
Lessee, Lease, Description [Line Items]
Operating Leases, Lease right-of-use asset	$ 89,600
Property, plant and equipment
Lessee, Lease, Description [Line Items]
Financing Leases, Lease right-of-use asset	9,900
Accrued expenses
Lessee, Lease, Description [Line Items]
Operating lease liabilities (current)	22,200
Finance lease obligations - short term
Lessee, Lease, Description [Line Items]
Finance lease liabilities (current)	1,800
Other long-term liabilities
Lessee, Lease, Description [Line Items]
Operating lease liabilities (non-current)	72,300
Finance lease obligations - long term
Lessee, Lease, Description [Line Items]
Finance lease liabilities (non-current)	$ 18,800

Leases - Additional Lease Infor

Leases - Additional Lease Information (Details)	3 Months Ended
	Dec. 28, 2019USD ($)
Non-cash impact of re-measuring right of use assets and operating lease liabilities	$ 2,400,000
Operating lease cost	7,000
Finance lease cost - amortization of right-of-use assets	300
Finance lease cost - interest cost	300
Operating cash flows from finance leases	300
Operating cash flows from operating leases	5,900
Financing cash flows from finance leases	400
Total cash paid for amounts included in the measurement of lease liabilities	6,600
ROU assets arising from entering into new operating lease obligations	$ 1,400
Maximum
Lessee, Operating And Finance Lease, Remaining Lease Term	15 years

Leases - Lease Liability Maturi

Leases - Lease Liability Maturity Schedule (Details)	Dec. 28, 2019USD ($)
Leases [Abstract]
2020 remaining	$ 17,800
2021	22,200
2022	17,300
2023	10,700
2024	8,700
Thereafter	24,000
Total future minimum lease payments	100,700
Less: imputed interest	(6,200)
Present value of lease liabilities	94,500
2020 remaining	2,100
2021	2,800
2022	3,000
2023	3,000
2024	3,000
Thereafter	11,500
Total future minimum lease payments	25,400
Less: imputed interest	(4,800)
Present value of lease liabilities	$ 20,600

Fair Value Measurements - Fair

Fair Value Measurements - Fair Value Assets and Liabilities Measured on Recurring Basis (Detail) $ in Millions	Dec. 28, 2019USD ($)
Assets:
Assets measured at fair value on a recurring basis	$ 11.2
Liabilities:
Total	10.5
Interest Rate Swap
Assets:
Assets measured at fair value on a recurring basis	10.4
Foreign currency option contracts
Assets:
Assets measured at fair value on a recurring basis	0.3
Forward foreign currency contracts
Assets:
Assets measured at fair value on a recurring basis	0.5
Contingent Consideration Type
Liabilities:
Contingent consideration	9.3
Forward Contracts
Liabilities:
Forward foreign currency contracts	1.2
Quoted Prices in Active Market for Identical Assets (Level 1)
Assets:
Assets measured at fair value on a recurring basis	0
Liabilities:
Total	0
Quoted Prices in Active Market for Identical Assets (Level 1) | Interest Rate Swap
Assets:
Assets measured at fair value on a recurring basis	0
Quoted Prices in Active Market for Identical Assets (Level 1) | Foreign currency option contracts
Assets:
Assets measured at fair value on a recurring basis	0
Quoted Prices in Active Market for Identical Assets (Level 1) | Forward foreign currency contracts
Assets:
Assets measured at fair value on a recurring basis	0
Quoted Prices in Active Market for Identical Assets (Level 1) | Contingent Consideration Type
Liabilities:
Contingent consideration	0
Quoted Prices in Active Market for Identical Assets (Level 1) | Forward Contracts
Liabilities:
Forward foreign currency contracts	0
Significant Other Observable Inputs (Level 2)
Assets:
Assets measured at fair value on a recurring basis	11.2
Liabilities:
Total	1.2
Significant Other Observable Inputs (Level 2) | Interest Rate Swap
Assets:
Assets measured at fair value on a recurring basis	10.4
Significant Other Observable Inputs (Level 2) | Foreign currency option contracts
Assets:
Assets measured at fair value on a recurring basis	0.3
Significant Other Observable Inputs (Level 2) | Forward foreign currency contracts
Assets:
Assets measured at fair value on a recurring basis	0.5
Significant Other Observable Inputs (Level 2) | Contingent Consideration Type
Liabilities:
Contingent consideration	0
Significant Other Observable Inputs (Level 2) | Forward Contracts
Liabilities:
Forward foreign currency contracts	1.2
Significant Unobservable Inputs (Level 3)
Assets:
Assets measured at fair value on a recurring basis	0
Liabilities:
Total	9.3
Significant Unobservable Inputs (Level 3) | Interest Rate Swap
Assets:
Assets measured at fair value on a recurring basis	0
Significant Unobservable Inputs (Level 3) | Foreign currency option contracts
Assets:
Assets measured at fair value on a recurring basis	0
Significant Unobservable Inputs (Level 3) | Forward foreign currency contracts
Assets:
Assets measured at fair value on a recurring basis	0
Significant Unobservable Inputs (Level 3) | Contingent Consideration Type
Liabilities:
Contingent consideration	9.3
Significant Unobservable Inputs (Level 3) | Forward Contracts
Liabilities:
Forward foreign currency contracts	$ 0

Fair Value Measurements - Addit

Fair Value Measurements - Additional Information (Detail) - USD ($) $ in Millions	3 Months Ended
	Dec. 28, 2019	Dec. 29, 2018
Fair Value, Off-balance Sheet Risks, Disclosure Information [Line Items]
Intangible asset impairment charges	$ 30.2	$ 0
Borrowed principal	1,000
Credit Agreement
Fair Value, Off-balance Sheet Risks, Disclosure Information [Line Items]
Borrowed principal	1,500
Securitization Program
Fair Value, Off-balance Sheet Risks, Disclosure Information [Line Items]
Borrowed principal	250
2025 Senior Notes
Fair Value, Off-balance Sheet Risks, Disclosure Information [Line Items]
Fair value of debt instrument	983.4
2028 Senior Notes
Fair Value, Off-balance Sheet Risks, Disclosure Information [Line Items]
Fair value of debt instrument	424
Medical Aesthetics
Fair Value, Off-balance Sheet Risks, Disclosure Information [Line Items]
Intangible asset impairment charges	$ 30.2

Business Combination - Narrativ

Business Combination - Narrative (Details) $ / shares in Units, shares in Millions, $ in Millions

Nov. 21, 2019USD ($)shares

Oct. 01, 2019USD ($)

Aug. 01, 2019USD ($)

Oct. 01, 2018USD ($)

Jul. 31, 2018

Dec. 11, 2017

Nov. 30, 2019USD ($)

Sep. 30, 2019$ / shares

Sep. 28, 2019USD ($)

Mar. 30, 2019USD ($)

Dec. 28, 2019USD ($)

Nov. 20, 2019

Business Acquisition [Line Items]

Consideration transferred

$ 69.3

Ownership percentage

78.00%

Goodwill

$ 2,563.7

$ 2,594.2

Equity interest in acquiree, remeasurement gain

$ 3.2

Consideration related to equity method investment

17.9

Consideration related to newly acquired shares

$ 12.6

Consideration, portion related to loan repayment

30.2

Business Combination, Consideration related to fair value of noncontrolling interest

8.6

Discount rate percentage

0.120

Emsor

Business Acquisition [Line Items]

Period of cumulative revenue to trigger payment of contingent consideration liability

2 years

Faxitron | Developed technology

Business Acquisition [Line Items]

Weighted average period

9 years

Faxitron | Customer relationships

Business Acquisition [Line Items]

Weighted average period

9 years

Faxitron | Trade names

Business Acquisition [Line Items]

Weighted average period

8 years 3 months 18 days

Focal Therapeutics

Business Acquisition [Line Items]

Consideration transferred

$ 12.5

$ 120.1

Purchase price withheld

$ 14

$ 1.5

Period for payment of contingent consideration liabilities

1 year

Goodwill

$ 31.1

Focal Therapeutics | Developed technology

Business Acquisition [Line Items]

Identifiable intangible assets

$ 83.1

Weighted average period

11 years

Focal Therapeutics | In-process research and development

Business Acquisition [Line Items]

Identifiable intangible assets

$ 11.4

Focal Therapeutics | In-process research and development | Minimum | Discount Rate

Business Acquisition [Line Items]

Intangible assets, fair value (percentage)

15.50%

Focal Therapeutics | In-process research and development | Maximum | Discount Rate

Business Acquisition [Line Items]

Intangible assets, fair value (percentage)

16.50%

Focal Therapeutics | Trade names

Business Acquisition [Line Items]

Identifiable intangible assets

$ 2.7

Weighted average period

13 years

SuperSonic Imagine

Business Acquisition [Line Items]

Consideration transferred

12.6

$ 18.2

Equity interest in acquiree, Percentage

46.00%

Goodwill

28.7

Other assets

$ 6.5

Percentage of outstanding shares acquired

46.00%

50.00%

Cash tender offer price (per share) | $ / shares

$ 1.50

Shares acquired | shares

7.6

Other Income

Business Acquisition [Line Items]

Income (loss) from equity method investments

$ 3.3

Business Combination - Purchase

Business Combination - Purchase Price Allocation (Details) - USD ($) $ in Millions	Dec. 28, 2019	Sep. 28, 2019	Oct. 01, 2018
Purchase Price Allocation [Line Items]
Goodwill	$ 2,594.2	$ 2,563.7
Focal Therapeutics
Purchase Price Allocation [Line Items]
Cash			$ 2.2
Accounts receivable			2
Inventory			7.9
Other assets			0.5
Accounts payable and accrued expenses			(5.6)
Long-term debt			(2.5)
Deferred income taxes, net			(12.7)
Goodwill			31.1
Purchase Price			120.1
Focal Therapeutics | Developed technology
Purchase Price Allocation [Line Items]
Identifiable intangible assets			83.1
Focal Therapeutics | In-process research and development
Purchase Price Allocation [Line Items]
Identifiable intangible assets			11.4
Focal Therapeutics | Trade names
Purchase Price Allocation [Line Items]
Identifiable intangible assets			$ 2.7

Business Combinations Business

Business Combinations Business Combinations - Purchase Price Allocation, SuperSonic (Details) - USD ($) $ in Millions	Dec. 28, 2019	Nov. 21, 2019	Sep. 28, 2019
Business Acquisition [Line Items]
Goodwill	$ 2,594.2		$ 2,563.7
SuperSonic Imagine
Business Acquisition [Line Items]
Cash		$ 2.6
Accounts receivable		7.1
Inventory		10
Other assets		6.5
Other assets		4.4
Accounts payable and accrued expenses		13
Deferred revenue		1.8
Short and long-term debt		(8.8)
Other liabilities		(3.8)
Developed technology		33.2
Customer relationships		3.1
Trade names		3.5
Deferred income taxes, net		(2.4)
Goodwill		28.7
Purchase Price		$ 69.3

Disposition (Details)

Disposition (Details) - USD ($) $ in Millions	Nov. 20, 2019	Dec. 28, 2019	Dec. 29, 2018
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Intangible asset impairment charges		$ 30.2	$ 0
Disposal Group, Disposed of by Sale, Not Discontinued Operations [Member] | Medical Aesthetics [Domain]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Disposal Group, Including Discontinued Operation, Consideration	$ 205
Proceeds from Divestiture of Businesses	$ 153.4
Cost of revenues
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Intangible asset impairment charges		25.8
Operating Expense [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Intangible asset impairment charges		$ 4.4

Disposition - Schedule of Asset

Disposition - Schedule of Assets and Liabilities Held For Sale (Details) - Medical Aesthetics [Domain] - Disposal Group, Disposed of by Sale, Not Discontinued Operations [Member]	Dec. 28, 2019USD ($)
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Cash	$ 10,700
Accounts Receivable	59,600
Inventory	90,600
Prepaid expenses and other current assets	7,700
Property, plant, and equipment	4,000
Intangible assets	28,200
Other assets	9,800
Total assets held-for-sale	210,600
Accounts payable	12,300
Accrued expenses	49,000
Deferred revenue	16,600
Total liabilities held-for-sale	$ 77,900

Borrowings and Credit Arrange_3

Borrowings and Credit Arrangements - Company's Borrowings (Detail) - USD ($) $ in Millions	Dec. 28, 2019	Sep. 28, 2019
Debt Instrument [Line Items]
Current portion of long-term debt	$ 302.2	$ 271.4
Total long-term debt obligations	2,769.4	2,783.6
Total debt obligations	3,071.6	3,055
Term Loan
Debt Instrument [Line Items]
Current portion of long-term debt	46.8	37.4
Long term debt obligations. excluding convertible notes	1,434.3	1,452.4
Securitization Program
Debt Instrument [Line Items]
Current portion of long-term debt	250	234
2025 Senior Notes
Debt Instrument [Line Items]
Long term debt obligations. excluding convertible notes	937.8	937.3
2028 Senior Notes
Debt Instrument [Line Items]
Long term debt obligations. excluding convertible notes	394.1	393.9
SSI [Member]
Debt Instrument [Line Items]
Current portion of long-term debt	5.4	0
Long term debt obligations. excluding convertible notes	$ 3.2	$ 0

Borrowings and Credit Arrange_4

Borrowings and Credit Arrangements - Additional Information (Detail) - USD ($)	3 Months Ended
	Dec. 28, 2019	Dec. 29, 2018	Sep. 28, 2019	Jan. 19, 2018	Oct. 10, 2017
Debt Instrument [Line Items]
Long-term debt	$ 3,071,600,000		$ 3,055,000,000
Debt extinguishment losses	0	$ 800,000
Payment of debt issuance costs	0	2,700,000
Senior notes				$ 1,000,000,000	$ 350,000,000
Borrowed principal	1,000,000,000
Long-term Debt, Current Maturities	$ 302,200,000		271,400,000
Amended Revolver [Member] | Percentage Added to Eurodollar Rate
Debt Instrument [Line Items]
Basis spread on variable rate	1.25%
Amended Term Loan | Percentage Added to Eurodollar Rate
Debt Instrument [Line Items]
Basis spread on variable rate	1.25%
Amended Credit Agreement
Debt Instrument [Line Items]
Debt extinguishment losses		$ (800,000)
Maximum range of present value of cash flow percentage		10.00%
Direct third party costs interest expense		$ 800,000
Payment of debt issuance costs		$ 1,900,000
Credit Agreement
Debt Instrument [Line Items]
Borrowed principal	$ 1,500,000,000
2025 Senior Notes
Debt Instrument [Line Items]
Stated interest rate	4.375%
Accounts Receivable Securitization
Debt Instrument [Line Items]
Borrowed principal	$ 250,000,000
Accounts Receivable Securitization
Debt Instrument [Line Items]
Long-term Debt, Current Maturities	$ 250,000,000		$ 234,000,000
Amended Term Loan | Amended Credit Agreement
Debt Instrument [Line Items]
Periodic principal payment period	3 months
Senior Notes | 2025 Senior Notes
Debt Instrument [Line Items]
Stated interest rate	4.375%
Offering price of principal amount				$ 1	$ 1
Senior Notes | 2028 Senior Notes
Debt Instrument [Line Items]
Stated interest rate	4.625%			4.625%
Offering price of principal amount				$ 1
2025 Senior Notes
Debt Instrument [Line Items]
Borrowed principal				600,000,000
Senior notes, face amount	$ 950,000,000
2028 Senior Notes
Debt Instrument [Line Items]
Borrowed principal				$ 400,000,000
Senior notes, face amount	$ 400,000,000

Borrowings and Credit Arrange_5

Borrowings and Credit Arrangements - Interest Expense Credit Agreement (Details) - USD ($) $ in Millions	3 Months Ended
	Dec. 28, 2019	Dec. 29, 2018
Line of Credit Facility [Line Items]
Interest expense	$ 15.7	$ 15.7
Credit Agreement
Line of Credit Facility [Line Items]
Interest expense	$ 13.6	$ 18
Weighted average interest rate	3.11%	3.82%
Interest rate at end of period	3.04%	3.88%

Borrowings and Credit Arrange_6

Borrowings and Credit Arrangements - Interest Expense Senior Notes (Details) - USD ($) $ in Millions	3 Months Ended
	Dec. 28, 2019	Dec. 29, 2018	Jan. 19, 2018
Line of Credit Facility [Line Items]
Interest expense	$ 15.7	$ 15.7
2025 Senior Notes
Line of Credit Facility [Line Items]
Stated interest rate	4.375%
Senior Notes | 2028 Senior Notes
Line of Credit Facility [Line Items]
Stated interest rate	4.625%		4.625%
Interest expense	$ 4.8	4.8
Senior Notes | 2025 Senior Notes
Line of Credit Facility [Line Items]
Stated interest rate	4.375%
Interest expense	$ 10.9	$ 10.9

Derivatives - Additional Inform

Derivatives - Additional Information (Details) - USD ($) $ in Millions	3 Months Ended		12 Months Ended
	Dec. 28, 2019	Dec. 29, 2018	Sep. 28, 2019
Derivative [Line Items]
Interest Rate Cap Agreements Aggregate Premium Payable	$ 1.5		$ 3.7
Borrowed principal	1,000
Loss reclassified from accumulated other comprehensive loss to the statement of income	(1.3)	$ (0.7)
Derivative Instruments, Gain (Loss) Reclassification from Accumulated OCI to Income, Estimated Net Amount to be Transferred	(1.5)
Interest Rate Cash Flow Hedge Asset at Fair Value	0		$ 0.1
Gain (Loss) on Foreign Currency Derivative Instruments Not Designated as Hedging Instruments	0	(1.7)
Unrealized Gain (Loss) on Foreign Currency Derivatives, Net, before Tax	1.5	$ 3.4
Notional Amount	77
Interest Rate Swap
Derivative [Line Items]
Derivative notional amount	$ 1,000
Variable interest rate	1.23%
Interest rate swap at fair value	$ 10.4
Foreign Exchange Option
Derivative [Line Items]
Derivative notional amount	124.2
Net unrealized loss	$ 1.5

Derivatives - Fair Value of Der

Derivatives - Fair Value of Derivative Financial Instruments (Details) - USD ($) $ in Millions	Dec. 28, 2019	Sep. 28, 2019
Interest Rate Swap
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Interest rate swap at fair value	$ 10.4
Derivative instruments designated as a cash flow hedge | Interest rate cap agreements
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Interest rate swap at fair value	10.4	$ 4.8
Derivative instruments designated as a cash flow hedge | Interest rate cap agreements | Prepaid expenses and other current assets
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Interest rate swap at fair value	0	0.1
Derivative instruments designated as a cash flow hedge | Interest Rate Swap | Other assets
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Derivative Asset, Fair Value, Gross Asset	10.4	4.7
Derivatives not designated as hedging instruments
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Derivative Asset, Fair Value, Gross Asset	0.8	2.9
Derivatives not designated as hedging instruments | Forward foreign currency contracts | Prepaid expenses and other current assets
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Interest rate swap at fair value	0.5	0.9
Derivatives not designated as hedging instruments | Forward foreign currency contracts | Accrued expenses
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Interest rate swap at fair value	1.2	0.1
Derivatives not designated as hedging instruments | Foreign currency option contracts | Prepaid expenses and other current assets
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Derivative Asset, Fair Value, Gross Asset	$ 0.3	$ 2

Derivatives - Schedule of Cash

Derivatives - Schedule of Cash Flow Hedges Included in Accumulated Other Comprehensive Income (Details) - USD ($) $ in Millions	3 Months Ended
	Dec. 28, 2019	Dec. 29, 2018
Derivative Instruments, Gain (Loss) [Line Items]
Amount of gain (loss) recognized in other comprehensive income, net of taxes:	$ 4	$ (3.9)
Changes in value of hedged interest rate swaps and interest rate caps, net of tax of $1.7 and $0.5 for the three months ended December 28, 2019 and December 29, 2018.	4	(3.9)
Interest Rate Swap
Derivative Instruments, Gain (Loss) [Line Items]
Amount of gain (loss) recognized in other comprehensive income, net of taxes:	4.3	0
Interest rate cap agreements
Derivative Instruments, Gain (Loss) [Line Items]
Changes in value of hedged interest rate swaps and interest rate caps, net of tax of $1.7 and $0.5 for the three months ended December 28, 2019 and December 29, 2018.	$ (0.3)	$ (3.9)

Derivatives - Gain (Loss) on Fa

Derivatives - Gain (Loss) on Fair Value Hedges Recognized in Earnings (Details) - USD ($) $ in Millions	3 Months Ended
	Dec. 28, 2019	Dec. 29, 2018
Derivative Instruments, Gain (Loss) [Line Items]
Gain (Loss) on Foreign Currency Derivative Instruments Not Designated as Hedging Instruments	$ 0	$ (1.7)
Derivative instruments not designated as hedges, gain (loss)	(3.2)	5.1
Forward foreign currency contracts
Derivative Instruments, Gain (Loss) [Line Items]
Forward foreign currency contracts	(1.5)	5.1
Foreign currency option contracts
Derivative Instruments, Gain (Loss) [Line Items]
Derivative instruments not designated as hedges, gain (loss)	$ (1.7)	$ 0

Commitments and Contingencies (

Commitments and Contingencies (Detail)	Oct. 07, 2016USD ($)	Mar. 04, 2016petition	Mar. 31, 2017USD ($)	Jul. 27, 2018USD ($)
Minerva
Loss Contingencies [Line Items]
Assessed damages				$ 4,800,000
Petitions filed | petition		2
Cynosure
Loss Contingencies [Line Items]
Plaintiff statutory damages on individual basis	$ 25
Payment of settlement compensation			$ 8,500,000

Net Income (Loss) Per Share - R

Net Income (Loss) Per Share - Reconciliation of Basic and Diluted Share Amounts (Detail) - shares shares in Thousands	3 Months Ended
	Dec. 28, 2019	Dec. 29, 2018
Earnings Per Share [Line Items]
Basic weighted average common shares outstanding	267,893	270,590
Weighted average common stock equivalents from assumed exercise of stock options and issuance of stock units	1,828	1,782
Diluted weighted average common shares outstanding	269,721	272,372
Outstanding Stock Options and stock units
Weighted-average anti-dilutive shares related to:
Weighted-average anti-dilutive shares (in shares)	1,290	3,339
Restricted stock units
Weighted-average anti-dilutive shares related to:
Weighted-average anti-dilutive shares (in shares)	1	4

Stock-Based Compensation - Stoc

Stock-Based Compensation - Stock-Based Compensation Expense in Consolidated Statements of Operations (Detail) - USD ($) $ in Millions	3 Months Ended
	Dec. 28, 2019	Dec. 29, 2018
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expense	$ 18.1	$ 17.1
Cost of revenues
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expense	2	2
Research and development
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expense	2.4	2.7
Selling and marketing
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expense	2.8	2.7
General and administrative
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expense	$ 10.9	$ 9.7

Stock-Based Compensation - Addi

Stock-Based Compensation - Additional Information (Detail) - USD ($) $ / shares in Units, shares in Millions, $ in Millions	3 Months Ended
	Dec. 28, 2019	Dec. 29, 2018
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Purchase of insurance contracts	$ 2.4	$ 0
Stock option plans
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options granted	0.8	0.9
Weighted-average exercise prices	$ 45.67	$ 40.96
Share-based compensation, stock option outstanding	5.7
Weighted-average exercise price of options outstanding	$ 37.66
Unrecognized compensation expense	$ 30.4
Weighted-average period for recognition of unrecognized stock-based compensation, years	2 years 9 months 18 days
Restricted stock units
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares granted	0.7	0.9
Restricted stock units (RSUs), weighted average grant date fair values	$ 45.64	$ 40.98
Unrecognized compensation expense	$ 85.9
Weighted-average period for recognition of unrecognized stock-based compensation, years	2 years 2 months 12 days
Performance Shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares granted	0.1	0.1
Restricted stock units (RSUs), weighted average grant date fair values	$ 45.65	$ 40.97
Market Based Awards
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares granted	0.1	0.1
Restricted stock units (RSUs), weighted average grant date fair values	$ 43.78	$ 55.13
Minimum eligible percentage to receive target number of shares of company's common stock	0.00%
Maximum eligible percentage to receive target number of shares of company's common stock	200.00%
Performance stock units vesting period	3 years
PSU Free Cash Flow [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares granted	0.1
Restricted stock units (RSUs), weighted average grant date fair values	$ 45.65
Maximum eligible percentage to receive target number of shares of company's common stock	200.00%
RSU, PSU, MSU
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number	2.6

Stock-Based Compensation - Weig

Stock-Based Compensation - Weighted-Average Assumptions Utilized to Value Stock Options (Detail) - USD ($)	3 Months Ended
	Dec. 28, 2019	Dec. 29, 2018
Share-based Payment Arrangement [Abstract]
Risk-free interest rate	1700000.00%	3.00%
Expected volatility	33.60%	34.30%
Expected life (in years)	4 years 9 months 18 days	4 years 9 months 18 days
Dividend yield	$ 0	$ 0
Weighted average fair value of options granted	$ 13.83	$ 13.41

Other Balance Sheet Informati_3

Other Balance Sheet Information - Inventories (Detail) - USD ($) $ in Millions	Dec. 28, 2019	Sep. 28, 2019
Balance Sheet Related Disclosures [Abstract]
Raw materials	$ 154.5	$ 166.1
Work-in-process	54	54.5
Finished goods	172.3	224.3
Inventories	$ 380.8	$ 444.9

Other Balance Sheet Informati_4

Other Balance Sheet Information - Property, Plant and Equipment (Detail) - USD ($) $ in Millions	Dec. 28, 2019	Sep. 28, 2019
Balance Sheet Related Disclosures [Abstract]
Equipment	$ 385.2	$ 379.2
Equipment under customer usage agreements	448.2	435.5
Building and improvements	170.2	196.7
Leasehold improvements	43.6	61.7
Land	40.7	46.3
Furniture and fixtures	15.1	17.5
Property, plant and equipment, gross	1,103	1,136.9
Less – accumulated depreciation and amortization	(651)	(666)
Property, plant and equipment, net	$ 452	$ 470.9

Business Segments and Geograp_3

Business Segments and Geographic Information - Additional Information (Detail)	3 Months Ended
	Dec. 28, 2019USD ($)Segment	Dec. 29, 2018USD ($)
Segment Reporting Disclosure [Line Items]
Number of reportable segments | Segment	5
Number of operating segments | Segment	5
Revenues | $	$ 850,500,000	$ 830,700,000
Concentration Risk, Customer	0	0
Intersegment
Segment Reporting Disclosure [Line Items]
Revenues | $	$ 0	$ 0

Business Segments and Geograp_4

Business Segments and Geographic Information - Segment Information (Detail) - USD ($) $ in Millions	3 Months Ended
	Dec. 28, 2019	Dec. 29, 2018	Sep. 28, 2019
Segment Reporting Information [Line Items]
Total revenues	$ 850.5	$ 830.7
Income (loss) from operations	124.8	140.5
Depreciation and amortization	94.4	118.8
Capital expenditures	31.5	22.6
Identifiable assets	6,311.9		$ 6,442.1
Diagnostics
Segment Reporting Information [Line Items]
Total revenues	311.5	296.6
Income (loss) from operations	49.5	43.3
Depreciation and amortization	59.1	61.8
Capital expenditures	18.1	14.4
Identifiable assets	2,232.9		2,276.6
Breast Health
Segment Reporting Information [Line Items]
Total revenues	331.1	324.7
Income (loss) from operations	93.9	97.8
Depreciation and amortization	10	9.3
Capital expenditures	6.4	2.1
Identifiable assets	1,199.3		1,127.8
Medical Aesthetics
Segment Reporting Information [Line Items]
Total revenues	65.3	79.8
Income (loss) from operations	(51)	(25.2)
Depreciation and amortization	4.1	25.5
Capital expenditures	1.4	1.1
Identifiable assets	132.7		159.3
GYN Surgical
Segment Reporting Information [Line Items]
Total revenues	119.1	108.4
Income (loss) from operations	31.5	27
Depreciation and amortization	21	22
Capital expenditures	5.3	3.5
Identifiable assets	1,303.4		1,328.6
Skeletal Health
Segment Reporting Information [Line Items]
Total revenues	23.5	21.2
Income (loss) from operations	0.9	(2.4)
Depreciation and amortization	0.2	0.2
Capital expenditures	0.1	0.3
Identifiable assets	31.7		27.3
Corporate
Segment Reporting Information [Line Items]
Capital expenditures	0.2	$ 1.2
Identifiable assets	$ 1,411.9		$ 1,522.5

Business Segments and Geograp_5

Business Segments and Geographic Information - Revenues by Geography (Detail)	3 Months Ended
	Dec. 28, 2019	Dec. 29, 2018
Schedule Of Geographical Segments [Line Items]
Revenues	100.00%	100.00%
United States
Schedule Of Geographical Segments [Line Items]
Revenues	74.40%	74.90%
Europe
Schedule Of Geographical Segments [Line Items]
Revenues	12.90%	12.20%
Asia-Pacific
Schedule Of Geographical Segments [Line Items]
Revenues	8.30%	8.40%
Rest of World
Schedule Of Geographical Segments [Line Items]
Revenues	4.40%	4.50%

Income Taxes (Details)

Income Taxes (Details) - USD ($) $ / shares in Units, $ in Millions	3 Months Ended
	Dec. 28, 2019	Dec. 29, 2018
Segment Reporting Information [Line Items]
Other Tax Expense (Benefit)		$ 20
Company's effective tax rate	296.10%	5.50%
Final Net Tax Benefit amount for Tax Cuts and Job Act		$ 5
Increase to income tax expense adoption of ASU 2016-16		29.1
Decrease in deferred tax liabilities due to ASC 2016-16		49.1
Increase to Net Income resulted from adoption of ASU 2016-16		$ 20
Increase to Earnings per Share resulted from adoption of ASC 2016-16		$ 0.07
Increase in deferred tax assets resulting from adoption of ASCU 2016-16		$ 2.9
Decease in accumulated deficit resulting from adoption of ASCU 2016-16		2.5
Decease to prepaid taxes resulting from adoption of ASCU 2016-16		$ 0.4
Medical Aesthetics [Domain]
Segment Reporting Information [Line Items]
Other Tax Expense (Benefit)	$ 312.2

Intangible Assets and Goodwil_2

Intangible Assets and Goodwill - Schedule of Intangible Assets (Detail) - USD ($) $ in Millions	Dec. 28, 2019	Sep. 28, 2019
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Value	$ 4,764	$ 4,786.6
Accumulated Amortization	3,397	3,326.8
Developed technology
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Value	3,909.3	3,927.7
Accumulated Amortization	2,716.7	2,654.8
Customer relationships
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Value	527.7	525.5
Accumulated Amortization	454.5	447.5
Trade names
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Value	244.7	245.4
Accumulated Amortization	173.6	171.1
Distribution agreement
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Value	0	2.5
Accumulated Amortization	0	0
Non-competition agreements
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Value	1.5	1.4
Accumulated Amortization	1	0.9
Business licenses
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Value	2.3	2.3
Accumulated Amortization	2.2	2.2
Total acquired intangible assets
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Value	4,685.5	4,704.8
Accumulated Amortization	3,348	3,276.5
Internal-use software
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Value	50.8	53.9
Accumulated Amortization	40.9	43.4
Capitalized software embedded in products
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Value	27.7	27.9
Accumulated Amortization	$ 8.1	$ 6.9

Intangible Assets and Goodwil_3

Intangible Assets and Goodwill - Schedule of Estimated Amortization Expense (Detail) $ in Millions	Dec. 28, 2019USD ($)
Goodwill and Intangible Assets Disclosure [Abstract]
Remainder of Fiscal 2020	$ 213.7
Fiscal 2021	263.6
Fiscal 2022	253.2
Fiscal 2023	155.8
Fiscal 2024	$ 144.8

Intangible Assets and Goodwil_4

Intangible Assets and Goodwill -Narrative (Details) - USD ($) $ in Millions	3 Months Ended
	Dec. 28, 2019	Dec. 29, 2018
Finite-Lived Intangible Assets [Line Items]
Intangible asset impairment charges	$ 30.2	$ 0
Medical Aesthetics
Finite-Lived Intangible Assets [Line Items]
Intangible asset impairment charges	30.2
Developed technology | Medical Aesthetics
Finite-Lived Intangible Assets [Line Items]
Intangible asset impairment charges	24.1
Customer relationships | Medical Aesthetics
Finite-Lived Intangible Assets [Line Items]
Intangible asset impairment charges	0.9
Trade names | Medical Aesthetics
Finite-Lived Intangible Assets [Line Items]
Intangible asset impairment charges	2
Distribution agreement | Medical Aesthetics
Finite-Lived Intangible Assets [Line Items]
Intangible asset impairment charges	$ 1.2

Product Warranties - Product Wa

Product Warranties - Product Warranty Activity (Detail) - USD ($) $ in Millions	3 Months Ended
	Dec. 28, 2019	Dec. 29, 2018
Movement in Standard and Extended Product Warranty, Increase (Decrease) [Roll Forward]
Balance at Beginning of Period	$ 13.9	$ 15.9
Provisions	3.8	2.6
Standard and Extended Product Warranty Accrual, Additions from Business Acquisition	0.5	0
Settlements/ Adjustments	(4.1)	(3.4)
Balance at End of Period	$ 14.1	$ 15.1

Accumulated Other Comprehensi_3

Accumulated Other Comprehensive Income (Detail) - USD ($) $ in Millions	3 Months Ended
	Dec. 28, 2019	Dec. 29, 2018	Sep. 28, 2019
Accumulated Other Comprehensive Income (Loss) [Line Items]
Accumulated other comprehensive loss	$ (42.3)
Changes in foreign currency translation adjustment	8.3	$ (3.2)
Other Comprehensive (Income) Loss, Defined Benefit Plan, after Tax and Reclassification Adjustment, Attributable to Parent		0
Changes in value of hedged interest rate swaps and interest rate caps, net of tax of $1.7 and $0.5 for the three months ended December 28, 2019 and December 29, 2018.	4	(3.9)
Accumulated other comprehensive loss	(28.7)
Foreign Currency Translation
Accumulated Other Comprehensive Income (Loss) [Line Items]
Accumulated other comprehensive loss	(41.4)	(26.6)
Changes in foreign currency translation adjustment	8.3	(3.2)
Amounts reclassified to statement of income	0	0
Accumulated other comprehensive loss	(33.1)	(29.8)
Marketable Securities
Accumulated Other Comprehensive Income (Loss) [Line Items]
AOCI, Debt Securities, Available-for-sale, Adjustment, after Tax			$ 3.5
Changes in unrealized holding gains and losses on available-for-sale securities, net of tax of$0.2 for the three months ended December 30, 2017:	4
Amounts reclassified to statement of income	0
Pension Plans
Accumulated Other Comprehensive Income (Loss) [Line Items]
Accumulated other comprehensive loss	(1.7)	(1.1)
Other Comprehensive (Income) Loss, Defined Benefit Plan, after Tax and Reclassification Adjustment, Attributable to Parent	0
Amounts reclassified to statement of income	0	0
Accumulated other comprehensive loss	(1.7)	(1.1)
Hedged Interest Rate Caps
Accumulated Other Comprehensive Income (Loss) [Line Items]
Accumulated other comprehensive loss	(2.7)	2.2
Changes in value of hedged interest rate swaps and interest rate caps, net of tax of $1.7 and $0.5 for the three months ended December 28, 2019 and December 29, 2018.	0	(3.9)
Amounts reclassified to statement of income	(1.3)	(0.7)
Accumulated other comprehensive loss	(1.4)	(1)
Total
Accumulated Other Comprehensive Income (Loss) [Line Items]
Accumulated other comprehensive loss	(42.3)	(25.5)
Other Comprehensive Income (Loss) before Reclassifications, Tax	12.3	(7.1)
Amounts reclassified to statement of income	(1.3)	(0.7)
Accumulated other comprehensive loss	(28.7)	$ (31.9)
Interest Rate Swap [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Accumulated other comprehensive loss	$ 7.5

Share Repurchase Share repurcha

Share Repurchase Share repurchase (Details) - USD ($) shares in Millions	Aug. 01, 2018	Dec. 28, 2019
Equity [Abstract]
Total repurchase authorization	$ 500,000,000
Stock Repurchased During Period, Shares		1.5
Repurchase of equity		$ 80,900,000
Stock Repurchase Program, Remaining Authorized Repurchase Amount		130,600,000
Stock repurchased subsequent to period		900,000
Consideration paid for share repurchase subsequent to period		50,000,000
ASR Authorized		205,000,000
ASR Shares Repurchased during the period		3,300,000
Amount paid during the period under ASR Agreement		$ 164,000,000